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Rationale: Patients suffering from chronic radiation-induced small bowel disease (RISBD) 
after cancer treatment have similar symptoms as patients with IBS (irritable bowel 
syndrome), despite dissimilar pathological origin. The low FODMAP (fermentable oligo-, di-
, monosaccharides and polyols) diet (LFD) is a widespread management strategy for IBS. 
The aim of the conducted study was to investigate the effects of LFD on symptoms and 
health related quality of life (HRQOL) for patients with chronic RISBD.   
 
Methods: In an open pilot study, 11 patients with RISBD related IBS symptoms were 
instructed to follow LFD throughout a 4-week intervention period. IBS Severity Scoring 
System (IBS-SSS) and IBS Symptom Questionnaire (IBS-SQ) were used to assess 
symptoms. An Ad hoc questionnaire measured grade of damage and typical RISBD 
complaints. Short Form Nepean Dyspepsia Index (SF-NDI) and 12-item Short Form Health 
Survey (SF-12) were used to evaluate HRQOL. A 3-day food record was used to estimate 
baseline intake of FODMAPs, to reveal dietary changes and to assess adherence to the diet. 
All schemes were completed at baseline and at 4 weeks.  
 
Results: FODMAP intake was successfully reduced, and main additional changes in the diet 
were reduced intake of energy, carbohydrates and fiber. The adherence to the diet was high 
(mean 94.8%). IBS symptoms improved significantly based on mean total score of IBS-SSS 
and IBS-SQ, which changed from 310.2±60.7 to 171.4±107.2 (p=0.001) and 27.4±4.1 to 
15.7±10.1 (p=0.002), respectively. The severity of abdominal pain, abdominal distension, 
belching/flatulence, constipation, diarrhea, early satiety, dissatisfaction with bowel habits and 
interference with life in general, improved significantly. Tendencies of improvement were 
also measured in comorbidity complaints and typical RISBD complaints. HRQOL improved 
based on SF-NDI total score, which changed from 30.5±9.4 to 18.3±8.2 (p=0.001) and based 
on mental (p=0.047) and physical (p=0.134) component summary score of SF-12.  
 
Conclusions: The low FODMAP diet seems effective in alleviating IBS symptoms, and 
improving HRQOL in patients with RISBD. High compliance to LFD is possible with 
adequate diet counseling and continuous guidance. Further controlled studies with larger 
sample size should be conducted to verify our results and hopefully enable the 
implementation of LFD as a future management strategy for chronic RISBD.   
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1. INTRODUCTION  
1.1 Radiation-induced Small Bowel Disease  
1.1.1 Background 
Radiation-induced small bowel disease (RISBD) is a common side effect following ionizing 
radiation treatment (RT) for cancer in the gastrointestinal (GI) tract, or in the surrounding 
organs (1). Because of localization close to specific organs, the cancer types related to this 
symptom disease are GI, gynecological and urological cancers. The terms used to describe 
this condition vary. Traditionally, the term “radiation enteritis/proctitis/colitis” has been used. 
However, inflammation may be misleading, as it is not a dominating feature. “Pelvic 
radiation disease” or “radiation-induced small bowel disease/damage” are probably more 
accurate. The designations “radiation enteropathy”, “radiation proctopathy” and “radiation 
colopathy” may be useful to define the localization. Because of the proximity to the small 
bowel, symptoms arising from different parts of the intestines are often overlapping and the 
condition should perhaps not be named anatomically specified (1). Still, the focus in this 
paper is damage to the small bowel, because small bowel based symptoms are likely to be 
influenced by diet. RISBD is often subdivided in acute and chronic damage (2). The acute 
symptoms are self-limiting and only present during the treatment period, normally with an 
onset between the first three weeks of treatment and lasting for six weeks after treatment (3). 
In this study we will focus on patients who suffer from chronic radiation injury, developed 
(by definition) between 18 months and several years after completion of radiation therapy. 
Prolonged radiation injury can also occur as a chronic continuation of acute damage (2).  
  
1.1.2 Pelvic radiation treatment 
RT aims to damage tumor DNA (deoxyribonucleic acid) to prevent cell division, or promote 
apoptosis and cell death. High energy protons or neutrons evokes free radicals and DNA 
strain damage (4). The cells of normal tissue are less sensitive but are also affected in the 
process. To make it possible for normal tissue to regenerate, the radiation is given in 
fractions, e.g. one daily fraction five days a week for up to seven weeks. The dose, the 
radiation field and the fraction schedule are planned in advance. The administration of each 
fraction is painless and completed within a few minutes (5).  
The dosage given is registered as total amount of Gray (Gy), which reflects how much energy 
the area receives. This normally varies from 50-70 Gy for pelvic tumors (6). RT can be given 
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as external radiation, internal radiation (brachytherapy) or as a combination. Brachytherapy, 
by insertion of radioactive needles, allows more localized treatment and hence less damage to 
normal tissue (5). 
 
1.1.3 Epidemiology  
The number of new-diagnosed cancer cases in Norway, was in 2015 about 32600 (7). The 
cancer types that poses a risk to develop RISBD are all among the 10 most frequent; prostate 
29%, colon 18%, rectum 9% and gynecological 8%. This makes a total of about 11000 
patients who hypothetically are at risk for RISBD if receiving RT (7). In the UK, 20% of 
pelvic cancer cases are treated with radiation (8). The trend since 1965 for all these cancer 
types is that mortality is decreasing while survival and prevalence are increasing. An 
exception is gynecological cancers, where a decreasing incidence has been observed. 
Diagnostic methods and routines have improved, and the simultaneous shift to an 
ageing/older population, can explain the increased prevalence (7). The number of cancer 
survivors is increasing as treatment has been steadily improved (2). In Norway, 
approximately two of three cancer patients live five years after diagnosis (all cancer types) 
(7). Consequently the number of patients suffering from RISBD may also increase. Some 
reports suggest that up to 90% of cancer patients receiving pelvic RT will, to some degree, 
perceive a permanent change of bowel habits (9). This may be an overestimation, but 
generally, the condition is underreported, although half of the patients report that the late 
effects reduce quality of life (2). Based on the number of people receiving pelvic RT 
globally, this is estimated to encompass half a million people (10). Fecal urgency is believed 
to affect quality of life to the largest extent, and is reported in 3-53% of the patients (11, 12). 
Only a minor part of the affected patients are referred to a gastroenterology specialist (2). 
Suggested reasons for underreporting of the condition, is first of all the current lack of a clear 
definition and a routine management (2). Secondly, the discharge from follow-up after five 
years combined with the slow progress of chronic symptoms play a major role. The 
Norwegian National guidance for Gynecological Cancers suggest controls to be carried out 
every 3rd-6th month the first two years after finishing treatment, and then every 6th month the 
next five years (13). The main aim of the controls is to detect late effects and recurrent 
cancer. The most common late effects after RT for this cancer type are fatigue, 
abdominal/pelvic pain, GI affliction, urinary incontinence and infertility (14). Third, the fact 
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that patients are relieved being cured for cancer gives them a high tolerance for GI symptoms 
and make them less likely to seek help (11). 
Estimated proportions of patients affected by GI symptoms after RT are 66% for colorectal 
cancer, 40% for gynecological cancer and 30% for urological cancer (2). In the UK, this is 
equivalent to the number of patients diagnosed with inflammatory bowel disease (IBD) 
annually, but the medical attention and research funds are blatantly imbalanced (15).  
 
1.1.4 Pathophysiology 
The GI symptoms following pelvic radiation injury vary individually but include post-
prandial pain, abdominal discomfort/pain, diarrhea, constipation, obstruction, nausea, 
anorexia (reduced appetite), weight loss, bloating, steatorrhea, rectal bleeding, fecal 
urgency/incontinence and malabsorption of specific or multiple nutrients (4).  
 
The causes of symptoms are complex and multifactorial (Figure 1). It is important to 
remember, that not all symptoms seen after radiation are caused solely by the treatment, but 
could be due to e.g. already existing vulnerability for irritable bowel syndrome (IBS), celiac 
disease, small intestine bacterial overgrowth (SIBO), thyroid dysfunction, pancreatic 
insufficiency, drug side effects or change in dietary habits, indirectly connected to the cancer 
disease (2, 16). Also psychological stress, which cancer patients often suffer from, can 
promote GI symptoms. Despite of that, data suggesting organic causes for the symptoms do 
exist (2).  
 
The acute phase of radiation injury is histologically dominated by inflammation (6), and 
presents with clinical symptoms like loose stools, abdominal cramps, nausea and bleeding, 
normally managed by symptomatic and dietary treatment (11). Repetitive injury from 
radiation and free radicals provoke cell death, cytokine activation, abscess formation and 
arteriole swelling in intestinal cell layers. The cells of the small intestinal mucosa are rapidly 
dividing, and are therefor especially vulnerable (4). Lacking or abnormal neovascularization 
promotes ischemia and telangiectasia formation (17). The latter, can lead to rectal bleeding 
which occurs frequently in this patient group (2). The acute reaction is self-limiting and 
usually subsides soon after cessation of RT (11).  
In contrast, delayed/chronic radiation injury is dominated by progressive vascular changes, 
resulting in the hall-mark of the condition; fibrosis, which leads to both structural and 
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functional deteriorations, and also metabolic derangements (11). Inflammatory changes are 
less prominent. Clinical GI features are mainly dysmotility and malabsorption, but also fecal 
incontinence and bleeding. Severe situations can occur due to intestinal obstructions, fistulas 
or bowel perforation, but the main problem is often compromised quality of life due to 
diarrhea, fecal urgency, abdominal pain, bloating and flatulence (11).  
The underlying pathophysiology is not fully understood, but endothelial dysfunction is 
central in causing and perpetuating the delayed effect of radiation injury (17, 18). Prolonged 
thrombotic obstruction of small vessels releases multiple pro-inflammatory cytokines (IL1, 
IL2, TNF-α) and growth factors (TGF-β1, CTGF) (17, 19). A dose-dependent down-
regulation of thrombomodulin results in a consistent shift in the coagulation equilibrium 
towards reduced anticoagulation (20). The persisting pro-thrombotic state promotes low-
grade inflammation and visa versa, resulting in a chronic vicious circle. A simultaneous up-
regulation of protease-activated receptor-1 (PAR-1) in intestinal muscle cells may represent a 
link between endothelial dysfunction and radiation-induced fibrosis (21). In addition, RT-
provoked increased Rho Kinase signaling induces intestinal barrier dysfunction, leading to 
exposed mucosa and compromised secretory and absorptive functions (22). Some of the 
common symptoms can be explained directly by these mechanisms, but there are also 
secondary phenomena that contribute to GI symptoms. Examples are SIBO due to motility 
changes, bile salt malabsorption due to damage in terminal ileus and malabsorption of 
specific nutrients such as vitamin B12, lactose or other carbohydrates (4). 
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Figure 1: Overview over RISBD pathophysiology  
Radiation treatment induces the formation of free radicals, which promote changes in the cells of the 
bowel wall. Cell death, vascular changes, inflammation and swelling lead to fibrotic tissue with 
malfunctions that express as clinical symptoms (17-22). IBS; Irritabel bowel syndrome, TGF-β1; 
Transforming growth factor β1, CTGF; Connective tissue growth factor, IL; Interleukin, TNF-α; 
Tumor necrosis factor α, SIBO; Small intestine bacterial overgrowth. 
 
There are many factors that determine the degree of damage to the bowel tissue, and how 
prominent the symptoms become (23). First of all, clinical/technical factors play a major role, 
like radiation technology, dosage, regimen, size and site of radiation field and concurrent 
chemotherapy (1). It is estimated that a total dosage of 50 Gy will result in 50% of the 
patients developing RISBD within five years (24). The fact that concurrent use of 
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chemotherapy deteriorates the acute side effects of radiation, does not necessarily lead to 
worsen chronic late effects (4). In addition, there are patient-related factors involved in the 
risk of developing RISBD. Examples are cancer type and localization, comorbidities, 
previous abdominal surgery, genetic disposition and concurrent medications (1, 11). As 
endothelial vascularization is a central aspect of RISBD, conditions that reduce blood flow in 
general, like hypertension, diabetes, smoking and poor nutrition, can predispose to more 
severe late effects (23). Reduced body mass index (BMI) also contributes to a higher risk of 
developing chronic symptoms (4). Lately, it has been suggested that the composition and 
functionality of microbiota could play a role in the pathophysiological picture of RISBD (25).  
Andreyev et al. emphasize the importance of aiming to detect and understand the changes in 
GI physiology rather than focusing on the underlying pathology of the symptoms (10). They 
address 22 symptoms of pelvic radiation injury, and point out that by systematic investigation 
and treatment of the discovered abnormalities; improvement is possible (10, 26).  
 
1.1.5 Diagnosis  
RISBD patients are under-diagnosed and few are referred to further management. However, 
there are tools available to detect and assess the degree of tissue damage and symptom 
severity (11). Examples are the Royal Marsden Algorithm, the Radiation Therapy Oncology 
Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) tissue 
damage grading system and the Late Effect Normal Tissues/Subjective Objective 
Management Analysis (LENT/SOMA) table (11, 27, 28). These tools investigate the 
presence of damage based on symptoms, not by endoscopic or histologic examination. 
Therefore no distinction is made between different possible pathologies (4). This can be a 
major limitation when it comes to the choice of treatment, as for example diarrhea can have 
many possible causes. For initial diagnosis it is recommended to perform Selenium 
Homocholic acid taurine scan (SeHCAT)(bile acid malabsorption), glucose 
hydrogen/methane breath test, upper GI endoscopy with duodenal biopsies and flexible 
sigmoidoscopy (2). In addition, evaluation of biological markers such as C reactive protein 
(CRP), calprotectin and lactoferrin has been suggested, but they provide limited information 
(4). Possible differential diagnoses are recurrent neoplasia, colorectal cancer, celiac disease, 




The diverse and complex symptomatology of RISBD demands a comprehensive history 
taking and systematic investigation (2). This calls for a multidisciplinary cooperation and a 
holistic view on diagnosis, treatment and care. Practice guidance and an algorithm-based 
follow-up approach have been designed at the Royal Marsden Hospital (2, 29). This 
underlines the importance of collaboration between gastroenterologist, oncologist, surgeons, 
radiologist, laboratory service, dietitians, nurses, psychologist etc.  
The management of acute and chronic radiation injury can be subdivided into prophylactic 
approaches and treatment approaches. Radiation technology/methodology, and use of various 
medications can have a preventive effect on the development of RISBD (acute and delayed). 
Conformal radiotherapy techniques and intensity-modulated radiotherapy (IMRT) reduce the 
extent of radiation damage to normal surrounding tissue. Multiple beam intensity in a three-
dimensional manner narrows the radiation region and consequently allows higher doses to the 
tumor (30). The use of IMRT has expanded in Norway since the 1980’s (31). Other 
influencing factors are patient positioning, use of belly board, use of absorbable mesh slings, 
timing of treatment (circadian rhythm) and patients bladder content during RT (1, 32). 
Pharmacological agents can be used as protectors, mitigators or therapeutics and include 
antioxidants (like vitamin E gamma-tocotrienol), statins, somatostatin analoges (like 
pasireotide), sucralfate, teduglutide, balsalazide and nutritional supplements like glutamine 
and arginine (1, 4, 33, 34). They act by decreasing inflammation, improving the vascular 
function, or protecting the intestinal wall through various mechanisms. Some of these are 
already used in the clinic (e.g. statins), but others are hypothetically prophylactic and still 
under the scope of animal and human studies (e.g. pasireotide).  
 
Suggested treatment approaches are usually focused either on the symptoms or on 
complications. Some common symptoms can be alleviated by medications like anti-motility 
agents (Loperamide) or bile salt sequestering agents (cholestyramine) for diarrhea, analgesics 
for abdominal pain, and anti-emetics for nausea (1, 35). Loperamid is used regularly in this 
patient group. The effect is not well documented, and it only attenuates the symptoms 
without resolving the underlying problem (4). Anti-inflammatory agents like corticosteroids 
and sulphasalazine have shown to be effective in acute RISBD, but a recommendation for use 
in the chronic situation is not established (4). 
Probiotics and antibiotics can be used both to prevent and treat the commonly occurring 
SIBO. The effect is best documented for acute radiation injury and the optimal regimen, 
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dosage and duration is not clear (4, 36). If antibiotics are used to treat SIBO-induced 
diarrhea, this is normally only a temporary solution, as the cause of SIBO (motility change) is 
still present. It has been suggested that probiotics, prebiotics and dietary changes which 
reduce the thriving potential for the bacteria, can be a useful alternative approach (16). Other 
suggested dietary approaches include supplements of micronutrients, use of medium chained 
triglycerides (MCT), exclusion diets, supportive enteral diets and parenteral nutrition (1, 4, 
37-41). Surgery and endoscopic therapies should be avoided because of the vulnerability of 
the abnormal fibrotic and hypoxic tissue, but is necessary in some cases. This includes 
situations of sever strictures, fistulas, perforation, recurrent cancer or extensive and persisting 
symptoms that favor the establishment of short bowel syndrome (2, 4).  
 
The ischemic environment in fibrotic and/or necrotic tissue in the small bowel wall of RISBD 
patients is characterized by cell hypoxia, hypocellularity and hypovascularity, which can 
explain many of the known findings and symptoms. Hyperbaric oxygen (HBO) treatment has 
shown to promote angiogenesis, fibroplasia and tissue restructuring, resulting in an increased 
number of small blood vessels and better function of the ischemic tissue (16, 42, 43). The 
core-mechanism is a massive increase in tissue oxygen pressure, which stimulates 
neoangiogenesis in ischemic tissues due to a steep fall of the pO2. Patients are placed in a 
hyperbaric chamber, usually pressurized to 2.4 atmospheres (ATA), breathing 100% oxygen 
for 90 minutes daily until a total of 30-40 treatments (43). A review from 2002 found that 67 
of 74 studies have published positive results of HBO for chronic radiation damage (44). This 
is compatible with the results of a Norwegian study looking at health related quality of life 
(HRQOL) after HBO (43). Results from blinded, randomized, placebo-controlled trials are 
lacking on the field. Therefore, the Hyperbaric Oxygen Therapy II (HOT-II) study was 
conducted and published by Glover et al. in 2016 (45). This phase III study on 84 
participants, found no significant difference in change of symptom or HRQOL in the 
intervention group vs. the sham-group. This result is contradictory to the result of the first 
study of this type, the HORTIS study from 2008 (46), and Glover et al. stress the need for 
more level 1 evidence of this treatment type (45). The availability of hyperbaric oxygen 
treatment is generally limited to specialized centers (4). In Norway, treatment for not-acute 
indications is localized to the Center for hyperbaric medicine in Bergen, implying a long 
travel and an extensive treatment stay for many patients.  
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1.1.7 Role of diet in RISBD  
It is well known that a diet providing good nutritional status has impact the tolerance, 
completion and late effect development during and after pelvic RT. The relationship is also 
visa versa, as acute and chronic GI symptoms can lead to insufficient diet and reduced 
nutritional status (47). It is reported that 11-33% of patients receiving pelvic radiation are 
undernourished before starting treatment, and that 83% loose weight during the radiation 
period (39). At the Royal Marsden NHS Foundation, a specialist center for cancer treatment 
in London, the focus on RISBD has been emphasized for a long time (48). They started in 
2000 the GI and Nutrition Team (GIANT). From a one-year study from this clinic, it was 
reported that 36% (n=326) of the patients referred had a need for dietetic interventions (48). 
A review from UK found dietary advises to be the second most used treatment for late GI 
symptoms after the use of anti-diarrhea agents (49). Many factors in the clinical picture of 
RISBD, imply a risk for malnutrition and weight loss, like diarrhea, steatorrhea and vomiting, 
but also decreased intake, digestion or absorption (50).  
 
In Norway, brochures are available and handed out to patients after completing RT, where 
RISBD is noted as a possible late effect. These brochures include counseling information 
about food groups that could be excluded to reduce GI symptoms. The patients are 
encouraged to eat a diet low in lactose and fat, and to avoid spicy foods, foods with hard 
baking crust and foods that induce bowel gas. It also recommend to eat small and frequent 
meals, and to distribute the daily fat intake over several meals (51). To what extent this 
approach is presented and followed, or to what degree it has an effect, is not known. A study 
from UK used a questionnaire to evaluate how women at risk of RISBD where coping with 
GI symptoms (52). About half of the 95 women included, had changed their diet, but at the 
same time only half of them had received dietary advises. There seemed to be no correlation 
in who received counseling, and who changed diet. The most prominent diet changes were 
eating less fruit, fiber and vegetables. When avoiding these foods without sufficient 
supervision, the diet can be unbalanced, low in important micronutrients, and not in line with 
a healthy diet that reduces risk of lifestyle diseases (52).  
 
In clinical practice, a diet low in fermentable oligosaccharides, disaccharides, 
monosaccarides and polyols (FODMAP), has been tested for this group of patients. The 
experienced results seem promising in form of improvements of GI symptoms, but clinical 
trials have not yet been published (1). Many RISBD patients report postprandial discomfort, 
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and relate the severity and onset of symptoms to dietary intake. In a study, RISBD patients 
reported exacerbated GI symptoms after intake of bran muffin, berries, cabbage, brussels 
sprouts, broccoli, mixed salad, Ceaser salad, baked beans, lentils and nuts (53). Fifty percent 
of women with RISBD reported increased symptoms after consumption of these foods, 
compared to 21% of controls. Many of these foods contain FODMAPs. In addition, only 20% 
of the RISBD-group felt symptoms after eating food with high fat intake, despite the fact that 
many of them were trying to avoid high-fat foods (53).  
 
The rationale behind the idea that a low FODMAP diet (LFD) could have an effect on 
RISBD patients includes the fact that their symptoms are similar to what is seen in IBS, a 
condition successfully treated with LFD. In addition, the physiological damage to the small 
bowel can reduce the function of brush-border enzymes and luminal transport proteins, 
resulting in decreased carbohydrate breakdown and uptake (16). IBS patients often 
experience visceral hypersensitivity. This causes pain-related neural stimulation after normal 
postprandial distention of the gut lumen, followed by an abnormal motility response of 
distention. This again can explain symptoms like diarrhea and/or constipation often seen in 
RISBD patients (16). Many patients report their symptoms to be postprandial and related to 
intake of specific foods. Consequently, a large proportion of them have excluded different 
foodstuffs from their diet, either by own initiative, or after advise from health professionals 
(53). Based on this, studies investigating dietary interventions to limit the symptom-burden 
have been, and should be conducted.  
 
1.1.8 Associated conditions  
Urological problems, fertility- and sexual problems, lymphedema, neuropathy, fatigue, 
emotional and psychological problems are all conditions that are associated with pelvic 





1.2 The low FODMAP diet 
1.2.1 Rationale for the low FODMAP diet  
The low FODMAP diet was primarily introduced mainly for functional gastrointestinal 
disorders (FGID) like IBS and functional bloating (54). The acronym FODMAP is short for 
fermentable oligosaccharides, disaccharides, monosaccharides and polyols. This includes 
oligosaccharides known as fructans (fructo-oligosaccharides, FOS) and galactans (galacto-
oligosaccharides, GOS), the disaccharide lactose, the monosaccharide fructose in excess over 
glucose and polyols (sugar alcohols) (55). The rationale why these carbohydrates can 
promote symptoms in vulnerable guts is that they through different mechanisms give 
distension in the wall of the small and large bowel (Figure 2). The five different nutrients 
have different chemical characteristic and sources, but they all have in common that they are 
small (<10 sugar units) and therefore osmotic active, and that they are not fully absorbed in 
the small intestine and hence rapidly fermented by GI bacteria. Ingestion of FODMAP will 
therefore increase the volume in the intestines in form of gases (hydrogen, methane and 
carbon dioxide), liquid (osmotic activity draws water into the gut lumen) and also solids 
(FODMAP containing grains, fruits and vegetable are fiber sources i.e. bulking). In addition, 
the bacterial fermentation will result in production of short chain fatty acid (acetic, propionic 
and butyric acids), which can affect the motility of the intestinal wall. The distention of the 
bowel wall promotes pain and alters colonic motility and transit time (56). As in IBS, RISBD 
patients may have a dysbiosis in microbiota, which means an abnormal location or 
composition of bacteria (57). The increased luminal volume itself, together with motility 
changes, can explain the known symptoms of both IBS and RISBD (pain, discomfort, 
diarrhea, constipation, bloating, flatulence and fecal incontinence) (55).  
 
Poor uptake of most FODMAPs is common, but this physiological malabsorption is usually 
well tolerated in healthy people. Although everyone will experience some abnormal 
symptoms when consuming large enough quantities of FODMAPs, the threshold and the 
severity of symptoms vary individually. FODMAP intake is more problematic when having a 
vulnerable or damaged intestine by any cause (57). LFD has been studied extentively and the 
evidence for its effect for IBS is well documented (56, 58, 59). Because of this, and because 
of similar symptoms and disease characteristics, the diet has also been tried for other 
conditions like inflammatory bowel disease (IBD), diverticulitis, ileal pouch, celiac disease 




Figure 2: The progress from FODMAP intake to IBS symptoms  
FODMAPs are poorly absorbed in the small intestine and can cause bowel distention by gas, water 
and solids, which promote GI symptoms. FODMAP; Fermentable oligosaccharides, disaccharides, 
monosaccharides and polyols, IBS; Irritable bowel syndrome  
 
1.2.2 Different FODMAP groups 
The tolerance for the different FODMAP groups and the quantities vary between individuals 
(63). Distinctive subgroups of these carbohydrates will consequently be of individual 
importance when restricting FODMAPs from diet. Therefore, the rationale for the 
problematic digestion for each subgroup should be explained briefly for patients converting 
to the diet. This can improve the compliance (55). 
Fructose has a transport mechanism with low capacity when the monosaccharide is in excess 
over glucose. This is the case in some fruits, sweeteners like honey and in concentrated fruit 
(juice, dried fruit and large serves). The reason for this is that the fructose transporter with 
highest capacity, GLUT-2, demands coexistence of glucose for absorption. The individual 
capacity for free fructose can be measured by a hydrogen breath test. Low activity/lack of the 
lactose cleaving hydrolase, lactase, at the brush border is the reason why lactose is scarcely 
absorbed. This can be permanent or temporary, and can also be measured by a breath test. 
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Low amounts/activity of hydrolases also explains the reduced absorption of fructans and 
galactans. Fructans are chains of fructose and appear as storage of carbohydrates in cereals, 
fruits and vegetables. Sources of galactans are beans, lentils and peas. They are thought to be 
non-absorbable, and are either excreted or fermented by microbiota. Polyols can be 
problematic due to the lack of an active absorption mechanism, and therefore the uptake 
depends only on passive diffusion through pores. The amount absorbed consequently 
depends on molecule size, transit time and pore size (which vary throughout the small 
intestine and is affected by epithelial damage). Polyols are present in some fruits, mushrooms 
and as sweeteners (55).  
 
1.2.3 Application/implementation of the diet 
As the tolerance for FODMAPs will be exceeded if the total amount consumed is large 
enough, FODMAPs need to be restricted completely, not only certain subgroups individually 
(55). To see the effects on symptoms, the diet need to be withheld for 2-6 weeks (56). The 
approach will not cure the cause of the symptoms, but can potentially be symptom relieving. 
The diet has until now mostly been studied counseled by a dietitian in a one-to-one approach. 
This permits the counseling to be focused on food alternatives relevant for the individual 
patient, based on their regular eating habits (56). If symptom relief is achieved after some 
weeks on strict diet, the next step is to reintroduce FODMAP groups one by one, to find out 
which one, and in which amount the subgroups are tolerated. This second phase is called the 
reintroduction phase, and aims to customize a diet with minimal restrictions and at the same 
time minimal symptoms. The procedure is to systematically introduce specific amounts of 
foodstuff that are high in one FODMAP group but low in the others when being symptom 
free. If it’s tolerated, larger amounts are consumed over three days, and thereafter a new 
subgroup can be tried. If symptoms reoccur, the subgroup is not tolerated and a strict diet 
should be restarted until symptom control is re-achieved, before testing the next group. 
 
1.2.4 Limitations of the diet 
LFD has some disadvantages and is not the right solution for all individuals. For instance, 
prolonged adherence to the diet possibly reduces fructose absorption capacity. This, together 
with a restricted food variety, can imply a risk for inadequate intake of specific nutrients and 
prebiotics. Furthermore, some recent studies report that it can alter the composition of gut 
microbiota in an unfavorable way (55, 56). A study comparing LFD and a traditional 
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Australian diet, found that after 6-8 weeks on LFD, the abundance of health benefitting 
bacterial groups was reduced (61, 64). These groups of gut bacteria are the butyrate-
producing ones (Faecalibacterium Prausnitzii), which seem to be generally reduced also in 
patients with IBD. This underlines the uncertainty for safety of long-term restriction of 
FODMAPs. Not all IBS patients seem to be responders to the diet, reflecting the unclear 
mechanisms behind the symptoms, but also individual compositions of the intestinal 
microbiota (59, 65). 
Risks for inadequate intake of specific essential nutrients on a strict LFD is especially 
important for the intake of fiber and calcium. Close continuous counseling from a dietitian 
seems necessary both for adherence and safety, and this limits its accessibility (64). 
Combined with the lack of information about FODMAP content on food packages, the diet is 
resource-demanding in many ways (59).  
 
1.3 Study rationale  
The main reason to introduce the LFD for patients with RISBD is the similarity in symptoms 
between this condition and IBS. Symptoms like abdominal pain/discomfort, abnormal bowel 
habits, bloating and flatulence are seen in both illnesses, even though RISBD has an organic 
cause unlike IBS. In addition, the LFD shares some of the principles seen in the traditionally 
dietary advises given to patients after pelvic radiation. This is why clinical dietitians in 
Norway have tried the LFD approach for this patient group. The effect on symptoms seems 
promising, but there is lack of clinical trials to confirm (or disprove) this. The aim of our 





2. SUBJECTS AND METHODS  
2.1 The study 
The study was conducted as a master thesis in clinical nutrition at the Faculty of Medicine 
and Dentistry at the University of Bergen (UiB), in collaboration with the Section of 
Gastroenterology, Medical Department at Haukeland University Hospital (HUS). The study 
coordinator was master student Trine Larsen. The study protocol was approved by the 
Regional committee for medical and health research ethics (REC) for western Norway, May 
2016 (2016/567)(Appendix 1).  
 
2.2 Patient recruitment 
The period of recruitment was from late August 2016 to January 2017. Patient recruitment 
was conducted using multiple approaches to reach patients who fulfilled the inclusion 
criteria. This was necessary since this patient group is relatively under-diagnosed, and 
defined as outpatients who no longer suffer from cancer. Patients were recruited by 
advertisement through the Association of Gynecological Cancer in Norway; a patient 
association affiliated with the Norwegian Cancer Society. Advertisement was published on 
the webpage and on the Facebook page of both the national and the regional association in 
Bergen. In addition, the regional association sent information about the study to all their 
members as private e-mails. A call for participants was also made through the web page for 
Prostate Cancer, the National Association against Digestive Disorders and through lecturers 
at the National Healthcare Institution for Cancer; Montebello center, in Mesnali. Recruitment 
was also attempted through the list of patients referred to The Hyperbaric Medical Unit 
(HMU) at the Department of occupational medicine, the outpatient service at the Department 
of Gynecology and the Department of Medicine, all at HUS.  
 
The patients who filled the inclusion criteria were contacted by phone, and some contacted 
the master student unprompted by phone or email. The participants considered eligible for the 
study received a detailed, oral and written presentation of the study, and a written informed 
consent was signed (Appendix 2). As patients from many parts of Norway were included, the 
consent was handed in by e-mail, mail or during personal meeting. All participants were 
informed about the right to self-determination and that withdrawal from the study at any time 
would not affect further treatment.  
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2.2.1 Inclusion criteria  
- Subjects between 18-70 years of age 
- Signed informed written consent 
- Patients who suffer from radiation-induced small bowel disease  
- Patients with radiation-induced IBS symptoms referred to and/or accepted for HBO 
treatment  
- IBS symptoms confirmed by the Rome III-criteria  
- IBS symptoms with/without rectal bleeding  
2.2.2 Exclusion criteria  
- Patients already eating a diet low in FODMAPs (if so they have to stop the diet at 
least 3 weeks before entering the study)  
- Patients already receiving HBO treatment 
 
2.3 Study design  
This pilot study used a quantitative open, prospective, intervention design with an 
intervention group consisting of 11 subjects. After signing written consent, a start date for the 
4-week diet period was settled. The participants started the diet period consecutive according 
to recruitment and what was suitable for the individual participant. Figure 3 illustrates the 
chronological progress of the clinical study. Prior to the diet period, all subjects received 
counseling in how to follow the LFD. Written diet information, and lists of foodstuffs to 
exclude and alternatives to eat were handed out. The participants made a 3-day food record 
(Appendix 3), and questionnaires regarding IBS criteria, RISBD grading, GI symptoms and 
quality of life were completed. There were also made a short interview to collect baseline 
characteristics and information about the details of the cancer treatment. This was done in a 
one-to-one meeting at HUS. For participants who lived elsewhere in Norway than in the 
Bergen-area, the questionnaires were filled out at home and sent by e-mail or mail. These 
participants were given diet counseling by phone. The written information about the diet was 
developed by the master student in clinical nutrition (i.e. study coordinator), and was based 
on a booklet from the dietitians at HUS, supplemented by details from materials published by 
writer and blogger Julianne Lyngstad and the low FODMAP Diet Application from the 
Monash University, Australia. (Appendix 4 and 5)  
During the diet period, the participants were encouraged to contact the master student by 
phone or email at any time in case of questions or ambiguities of any kind regarding the diet. 
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During the last days of the diet period the subjects again made a 3-day food diary, and filled 
out new questionnaires. At this point they also filled a compliance scheme to register to what 
degree the diet had been followed, and how demanding the diet felt for them (Appendix 6). A 
similar scheme was completed also 4-6 weeks after the diet period (Appendix 7).  
 
After completing the study, the participants who achieved a decrease in IBS symptoms and/or 
an increased quality of life, were offered counseling in the second phase of the LFD. This 
phase is the reintroducing phase that aims to uncover the type and amount of the FODMAP 
subgroups that cause the individual subject symptoms, and which groups can be reintroduced 
to the diet (Appendix 8). 
 
2.3.1 Study timeline  
 
Figure 3: Study timeline 
RISBD; Radiation-induced small bowel disease, IBS-SSS; Irritable Bowel Syndrome Severity 
Scoring System, IBS-SQ; Irritable Bowel Syndrome Symptom Questionnaire, SF-12; 12-item Short 
Form Survey, SF-NDI; Short Form Nepean Dyspepsia Index 
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2.4 Hypothesis  
The aim of this pilot study was to answer the following questions: 
1. Are GI symptoms alleviated in patients suffering from RISBD when adapting to a low 
FODMAP diet?  If so, which symptoms are alleviated and to what degree?  
2. Will a low FODMAP diet have any influence on health related quality of life in subjects 
with RISBD?  
 
Null hypothesis: There will be no differences in symptoms or health related quality of life 
before and after an intervention with the low FODMAP diet. 
 
Alternative hypothesis: The study participants will experience a relief in symptoms and an 
increased health related quality of life after an intervention with the low FODMAP diet. 
 
2.5 Data collection methods  
2.5.1 Food record 
The participants were asked twice during the study period to do a prospective food record for 
three coherent days, including two weekdays and one weekend day. This method implies a 
self-reported registration off all foods and beverages consumed. In addition to the type, 
brand, ingredients and preparation method, the amount of food should be registered as 
accurate as possible. This can be done by either weighing all foods in advance or by 
estimating amounts by household utensils (66). The food record was a standardized scheme 
developed at the Department for Clinical Nutrition at HUS (Appendix 3). The method of 
using a 3-day prospective food record is the most validated one for measuring dietary intake 
(67). The first record was used to estimate the participants’ intake of FODMAP at baseline, 
and the second was used to evaluate adherence to LFD. Information about intake of energy, 
macronutrients, dietary fiber and calcium was also registered from the records, to evaluate 
possible changes from baseline to end of intervention. These data were obtained by plotting 
the food records into the Norwegian online diet tool Kostholdsplanleggeren (68).  
 
The baseline intake of FODMAP was calculated from the baseline food record, using the 
Swedish nutritional calculation program, Dietist Net Free. The program contains a recently 
added database developed by three former master students at UiB. They plotted FODMAP 
values from Australia, Denmark and Norway (63, 69-72). Norwegian values were only 
available for the content of lactose in dairy products. For mixed products the database values 
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of FODMAPs were estimated from Norwegian recipes at matprat.no, and the recalculation of 
household utilities to grams found in the Norwegian diet tool Kostholdsplanleggeren. Still the 
database in Dietist Net has limitations for mixed foods. For example was the FODMAP 
content of instant tomato soup and chocolate chip cookie registered as 0 g in the database. To 
estimate the content of such foods, we used traditional recipes and the ingredient list for the 
products together with values from Australian and Norwegian analysis. This was done for all 
the FODMAP containing foods and ingredients and thereafter the sum of FODMAPs in the 
respective meal was calculated. In addition to the sum of overall FODMAP intake, the 
contribution from different FODMAP-groups was registered to state the main source of 
FODMAPs for each participant. The FODMAP groups in the database are fructose, lactose, 
fructans, galactans, free fructose, polyols, GOS and FOS. The FODMAP intake was 
estimated only at baseline, not at 4 weeks. The FODMAP intake was assumed to be so 
negligible if the diet was followed properly, that the calculation would have been inaccurate. 
Instead, the compliance form filled at the same time point, was used to evaluate if the 
FODMAP intake was sufficiently low. 
 
2.5.2 Baseline characteristics questionnaire  
An Ad hoc questionnaire was used to register baseline characteristic of the participants and 
information about their former cancer treatment (Appendix 9). This questionnaire was, in 
contrast to the others, not handed out to the subjects to fill on their own. In stead, the study 
coordinator asked the questions verbally. This made it possible to ask follow-up questions if 
needed. The information collected by this form included details about the RT received; like 
number of fractions, dosage size, other concurrent treatment forms, medications, and also GI 
symptoms. In addition, factors that affect blood circulation like smoking, diabetes, blood 
pressure and earlier pelvic surgery, were noted.  
 
2.5.3 Ad hoc questionnaire for grading of radiation injury based on RTOG 
In order to register to what extent the participants suffered from RISBD, we used the 
Radiation Therapy Oncology Group and European Organization for Research and Treatment 
of Cancer (RTOG/EORTC) late radiation morbidity scoring scheme (27). It includes 
characteristics that classify five different grades of radiation damage to specific organs and 
tissue types. Grade 0 means absence of damage, and 5 means the damage led to death. Based 
on the characteristics for small and large intestine a questionnaire was compiled and handed 
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out to the patients (Appendix 10). This form was initially supposed to be completed only 
before the diet period, with intention to include the resulting grade as a baseline 
characteristic. However, the scheme was also completed after the diet period, as it in 
retrospect seemed suitable also to measure change in symptom severity.  
2.5.4 Rome III Diagnostic criteria for functional gastrointestinal disorders 
The Rome III Diagnostic criteria for IBS were used to assure that the subjects fulfilled the 
inclusion criteria for the study (73). The criteria are as follows: 
“Recurrent abdominal pain or discomfort at least 3 days/month in the last 3 months, 
associated with two or more of the following: 
• Improvement with defecation  
• Onset associated with a change in stool frequency  
• Onset associated with a change in form (appearance) of stool 
Symptom onset at least 6 months prior to the diagnosis, with the above criteria fulfilled for 
the last 3 months” (73) 
 
A Norwegian translation of the Rome III Diagnostic Questionnaire for Adult Functional GI 
Disorders was used to evaluate if the criteria were met (Appendix 11)(74). In addition, the 
participants were asked the criteria directly through questions in the Rome III and Kane et al. 
IBS-symptom questionnaire (described later). 
 
2.5.5 Assessment of symptoms 
To measure the intervention’s effect on symptoms, we used two different questionnaires. 
Despite the fact that the forms have some overlapping items, we wanted to assess the change 
in symptoms as accurate as possible, and therefor asked the participants to complete both.  
 
2.5.5.1 IBS-SSS: IBS-Severity Scoring System  
To measure subjective alteration of symptoms, the standardized and validated questionnaire 
Irritable Bowel Syndrome Severity Scoring System (IBS-SSS), was filled before and after the 
diet period (75). The scoring system contains five items rated with a 0-100 point visual 
analog scale (VAS). The items include severity and frequency of abdominal pain, severity of 
abdominal bloating, dissatisfaction with bowel habits and interference with life in general. 
Frequency of pain is rated as 1-10 days, and the answer is thereafter multiplied by 10 to 
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enable incorporation with the other items. The maximum total score of 500 indicates the 
worst degree of symptoms and the score can be used to classify IBS as in remission (<75), 
mild (75-175), moderate (175-300) or severe (>300). A reduction in the total score of ≥50 
points is considered a significant improvement. The scoring system fits the purpose of 
measuring improvement since it is known to be sensitive to change in a relative short period 
of time (75). In this study an extended version of IBS-SSS was used. In addition to the above-
mentioned five items, 10 questions regarding GI complaints and comorbidity symptom 
severity was asked (Appendix 12). The supplied questions are also rated as 0-100 point VAS 
scores and cover nausea, vomiting, early satiety, headache, backache, tiredness, belching 
and/or gas passing, heartburn, sudden urge to urinate, thigh-pain and pain in muscles and/or 
joints. The additional questions were compiled in Sweden but translated to Norwegian by 
master students at UiB in 2014.  
 
2.5.5.2 IBS-SQ: Rome III and IBS symptom questionnaire  
A combined questionnaire including the Rome III criteria for IBS, characterization of IBS 
subtype, and grading of symptoms was completed by participants before and after the diet 
period (Appendix 13). The first two parts are based on the IBS criteria from Rome III, and 
formulated by a Norwegian researcher group (76). The first part contains questions answered 
yes/no to judge if Rome III criteria are met. The second part asks about stool consistency and 
problems regarding defecation to characterize which subtype of IBS the subject suffers from; 
IBS-diarrhea (IBS-D), IBS-constipation (IBS-C) or IBS-mixed (IBS-M).  
The last part of this scheme is called IBS symptom questionnaire (IBS-SQ) and was created 
by Kane et al. and Mathias et al. (77, 78). It contains six items were the subjects grade their 
symptom severity from 0-10 for nausea, bloating, abdominal pain, constipation, diarrhea and 
anorexia (loss of appetite). The IBS-SQ defines participants to have active IBS symptoms if 
the total score (max 60) of all six items is ≥15.  
 
2.5.6 Assessment of quality of life 
To measure the intervention’s effect on health related quality of life we used two different 
questionnaires. Despite the fact that the forms have some overlapping items, we wanted to 





Health related quality of life was measured by Short Form Nepean Dyspepsia Index (SF-
NDI) (79). This questionnaire consists of 10 questions that can be divided in five sub-scales; 
tension, interference with daily activity, eating/drinking, knowledge/control and 
work/studies. The original version of NDI was developed in Australia, and consisted of 42 
items. This has later been shortened to 25 items, and thereafter 10 items, but still holds a high 
responsiveness (ability to measure change). The questions are asked by selecting alternatives 
from 1 (not at all/never) to 5 (extremely/all the time). This gives a total score of 10-50 points, 
with the higher score indicating worse functioning/ quality of life. An individual score for all 
five of the sub-scales was also calculated. A Norwegian translation of the SF-NDI has been 
validated for patients with subjective food hypersensitivity, including IBS, and this version 
was used in the current study (Appendix 14) (80).  
2.5.6.2 SF-12 
The generic Medical Outcome 12 item Short Form Health Survey (SF-12) was also used to 
measure HRQOL (Appendix 15). This questionnaire is a shortened version of the 36 item 
Short Form Health Survey (SF-36) that was developed for the Medical Outcomes Study 
(MOS) by RAND Health (81). This was translated to Norwegian in 1998 (82). Like in the 
original form the results of SF-12 are also obtained by eight domain scores, a physical 
composite summary score (PCS) and the mental composite summary score (MCS)(83). The 
PCS are derived from the domain scores for general health, vitality, physical functioning, 
role-physical and bodily pain, while the MCS derives from the domains for general health, 
vitality, social functioning, role-emotional and mental health. As the scheme is generic, it can 
be used to measure HRQOL in different diseases (83).  
The total score for PCS, MCS and the domain scores of SF-12 ranges from 0 to 100, with 
higher scores indicating better quality of life.  
 
2.5.7 Dietary compliance during 4-week diet period 
To measure adherence to LFD during the intervention period, a questionnaire developed in 
2014 by four former nutritional students at UiB was applied (Appendix 6). The questions ask 
about satisfaction with the diet, to what extent the diet was followed, details about possible 
deviations from the diet, how straining the diet was perceived and satisfaction with diet 
counseling. The form includes a combination of VAS-scales and multiple-choice questions.  
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2.5.8 Dietary compliance 4-6 weeks after diet period   
About one month after completing the study, the participants were asked to fill another 
compliance form. The aim was to assess the likelihood of adapting to the LFD as their regular 
diet, and to assess the progress of the reintroduction phase. This form was developed by the 
same group of students mentioned before, and includes both VAS-scale and multiple-choice 
questions (Appendix 7).  
 
2.6 Ethical considerations 
The study protocol (Appendix 16) was approved by REC west (Regional committee for 
medical and health research ethics, western Norway), May 2016 (protocol number: 
2016/567)(Appendix 1).  
Before inclusion all participants gave signed written informed consent. All personal data 
were kept anonymous and handled in a confidential manner. Participation in the study was 
voluntary and withdrawal was possible at any point without providing any justification.  
 
2.7 Data analysis  
All data from questionnaires and food records were plotted consecutively into a Microsoft 
Excel® data file. Statistical analyses were performed in GraphPad Prism version 7.0 for 
Macintosh (GraphPad Software Inc., San Diego, California, USA). Data were transferred to 
Prism after all data from 11 subjects had been collected.  
To test data normality D’Agustino & Pearson omnibus test was used. Data following a 
normal distribution were presented as mean ± SD (standard deviation), otherwise as median 
with IQR (interquartile range). Paired t-test was used to compare the two sets of data from 
baseline and after 4 weeks with LFD. To quantify associations between FODMAP intake, 
symptoms and quality of life, Pearson correlation analyses were performed. A P-value of 
0.05 or less was considered significant (*: p≤ 0.05, **: p≤ 0.01, ***: p≤ 0.001).  
 
2.7.1 SF-12 scoring  
To be able to calculate the PCS and MCS scores for SF-12 a free student licensure and an 
activation key for the use of scoring credits in the QualityMetric Health Outcomes™ Scoring 
Software 5.0, were requested and provided from Optum QualityMetric Incorporated. In prior 
to set PCS and MCS, four of the items in the questionnaire needed to be recoded. This was 
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necessary to achieve that higher values count for better quality of life for all items to enable 
comparison. The recoding was performed automatically when plotting the respondent’s 
results into the software, so that 1=5, 2=4, 3=3, 4=2 and 5=1. Scoring algorithms converted 
all eight dimension scaled from 0-100 were 100 is the highest possible HRQOL state. The 
PCS and the MCS are known to change with age and also depend on sex. SF-12 scores 
presented are not adjusted for age and sex, and hence the results of this study can only be 
used for individually comparison from baseline to end of intervention, not to compare 
HRQOL from other studies using SF-12.   
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3. RESULTS 
3.1 Recruitment  
Recruitment was done continuously from late August 2016 until January 2017. The study 
coordinator/master student contacted 11 potential participants, and 12 made contact after 
seeing advertisements. Nine patients did not fulfill the inclusion criteria, leaving 14 
participants for study inclusion (Figure 4). Of these 14 participants the majority (n=10) was 
recruited directly or indirectly through the National or Regional Association for 
Gynecological Cancer in Norway and Bergen. Five subjects contacted the study coordinator 
by own initiative through information from the advertisement. The remaining five of these 
participants were called via contact information given by already included participants. One 
patient showed interest after receiving information during a course at the Montebello center, 
and one saw the advertisement on the web page of the National Association against Digestive 
Disorders. An attempt to recruit patients through the Hyperbaric Medical Unit at HUS was 
made by calling patients on the referral and waiting list. This resulted in one included 
participant. The last patient was included after being referred to the study coordinator by a 
gastroenterologist from the Department of Medicine at HUS (Figure 5). Announcements 
through the Association for Prostate Cancer and the Department of Gynecology at HUS lead 
some patients to enquire more information about the study, but did for various reasons not 
contribute any extra participants to the study.  
 
Three patients dropped out of the study after being included. Two of these dropped out 
during the first week of intervention and reasons for withdrawal were that the diet seemed too 
demanding and not suitable with own experience of tolerable and problematic foodstuff, or 
that the timing was poor regarding the family life situation. A third participant dropped out 
during the last days of the LFD period. The reason was acute sickness in the close family 
preventing her to complete the last food record and questionnaires. Eleven participants 
completed the study.  
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Figure 4: Flow chart of the recruitment process  
HUS; Haukeland university hospital 
 
Figure 5: Pie chart of how patients were recruited to the study 
  
Contacted by the master student 
- 8: Hyperbaric Medical Unit, HUS 
- 2: Department of Medicine, HUS 
- 1: Department of Gynecology, HUS 
 
 
Contacted the master student through 
advertisement 
- 5: Gynecological Cancer Association 
- 1: Association for Digestive disorders 
- 1: Montebello Center 
- 4: Word of mouth 





- Did not fill criteria 
- Found the diet to 
demanding 
- Did not have time for 





















National Assosiation for Gynecological Cancer, 
Norway (facebook/web page) 
Regional Assosiation for Gynecological Cancer, 
Bergen (facebook/web page/mailing list) 
Center for hyperbaric medicin, Bergen 
National Healtcare institution for Cancer, 
Montebello center 
Word of Mouth 
National Assosiation against Digestive disorders, 
Norway 
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3.2 Demographics  
Baseline characteristics of the study population show a mean age of 46.6 years, mean BMI of 
27.7 kg/m2 and inclusion of exclusively female participants. Three male patients made 
contact/were contacted but they all found the diet to demanding, and therefor none were 
included. The complete baseline demographics are presented in Table 1.  
 
Table 1: Baseline demographics for the study population (n=11) at baseline  
Participants, n 11 
Male/Female, n  0/11 
Age, years, mean ± SD 46.6 ± 4.5 
BMI, kg/m2, mean ± SD 27.7 ± 6.9 
Cancer type, n 
Cervix cancer 






Total radiation dosage, Gy, mean± SD 63.7 ± 16.1 (n=10) 
Number of fractions, mean ± SD 27.2 ± 4.6 (n=10) 
Years since radiation treatment, median (IQR) 5 (2-16) 
Duration of GI-symptoms, years, median (IQR) 5 (2-10) 
Grade of damage in small bowel, n: 1, 2, 3, 4, 5 
Diarrhea, n (VAS mean ± SD) 
Abdominal cramps, n (VAS mean ± SD) 
Rectal mucus, n (VAS mean ± SD) 
Rectal bleeding, n (VAS mean ± SD) 
Constipation, n 
Fecal incontinence, n (times/week mean ± SD) 
2, 8, 1, 0, 0 
10 (64.4 ± 19.8) 
8 (46.5 ± 20.8) 
7 (41.1 ± 15.9) 
3 (30.1 ± 21.6) 
3  
10 (5.1± 2.8) 


















Data are presented in n, mean ± SD and median with IQR, SD; Standard deviation, IQR; Interquartile 
range 
 35 
3.2.1 Cancer history, radiation damage and duration of GI symptoms 
The majority of subjects had former cervix cancer (n= 9), one had vulva cancer and one had 
ovarian cancer (Table 1). Number of years since finishing RT was at median 5, ranging from 
0.6 to 39. In all but two participants the onset of the GI symptoms was during or right after 
RT and the duration since RISBD affliction onset hence had a median of 5 years. The 
majority had radiation damage grade 2, according to RTOG/EORTC scoring scheme. Seven 
participants had IBS-SSS total score equivalent to IBS-severe (>300), which also can reflect 
the grade of damage in the GI tract. The mean total received radiation dosage was 64 Gy, 
with a mean of 27 fractions. All participants fulfilled the Rome III criteria for IBS, and eight 
had the subtype IBS-diarrhea.  
 
3.3 Dietary intervention  
The mean baseline FODMAP intake was 22 g/day and the FODMAP group contributing 
most to the total was the disaccharide lactose (mean 10 g/day) (Table 2, Figure 6). The mean 
overall self-reported adherence to the diet was 94.8%. 
 
Table 2: Daily dietary intakes at baseline and at 4 weeks of intervention  
Data are presented in mean ± SD, SD; standard deviation, E%; energy percentage, P-value from 
unpaired t-test *: p≤ 0.05, **: p≤ 0.01 
Mean ± SD Baseline 4 weeks p-value 
Energy, kcal 1841 ± 636 1407 ± 448.5 0.004** 
Body weight, kg 77.4 ± 19.0 75.9 ± 18.7 0.006** 
Carbohydrates incl. fiber, g 
Fat, g, 
Protein, g 
215.9 ± 94.6 
72.3 ± 28.1 
74.4 ± 25.3 
152.9 ± 78.2 
57.9 ± 23.1 







46.5 ± 7.6 
36.8 ± 6.4 
17.4 ± 3.6 
42.0 ± 11.0 
38.4 ± 9.6 




Dietary fiber, g 18.8 ± 8.4 13.9 ± 5.4 0.025* 
Calcium, mg 672.5 ± 205.5 576.8 ± 240.3 0.332 
Total FODMAP, g 22.0 ± 11.9 Not calculated  
Lactose, g 9.9 ± 4.1 Not calculated  





Figure 6: FODMAP intake, and consumed amount of lactose/non-lactose FODMAPs 
at baseline 
 
From the food records at baseline and at 4 weeks, intakes of specific dietary components 
were estimated (Table 2). The mean total energy intake per day was significantly reduced 
with about 450 kcal from baseline to end of diet period (p=0.004)(Figure 7).  
 
 



















































Body weight was registered both before and after the diet intervention, and results are shown 
in Table 2. The mean change was a weight reduction of 1.6 kg (p=0.006)(Figure 8). The 




















Figure 8: Individual and mean change in weight for the study population  
Red line = mean  
 
 
Figure 9: Distribution between the three main energy sources at baseline and at 4 weeks 





































A detailed overview over the dietary intake is presented in Table 2. During the diet period, 
the participants changed their intake of macronutrients (Figure 9). A significant reduction 
was seen in carbohydrate intake, which decreased from mean 215.9 g/day to 152.9 g/day 
(Figure 10A), and the reduction in carbohydrate energy contribution was from a mean of 46.5 
E% to 42 E% during intervention (p=0.134). The mean fiber intake at baseline was 18.8 
g/day and decreased significantly to 13.9 g/day after 4 weeks on LFD (p=0.025)(Figure 10B). 
The intake of fat decreased from a mean of 72.3 g/day to 57.9 g/day (Figure 10C). This 
change was borderline significant (p=0.092). Despite this, the relative contribution from fat 
as an energy source increased due to changes in intake of other macronutrients (carbohydrate 
and protein). Energy provided by fat increased from 36.8 E% to 38.4 E% (p=0.508). Protein 
intake and contribution to total calories changed in a non-significant manner through the 
intervention. The amount of protein eaten fell from mean 74.4 g/day to 64.3 g/day (Figure 
10D) and the mean protein contribution to total energy intake increased from 17.4 E% to 19.3 
E%. Some participants consumed more calcium, but most of them consumed less at 4 weeks 
compared to baseline. The mean change in calcium intake was a decrease from 672.5 mg to 







Figure 10: Mean intake of carbohydrates (A), dietary fiber (B), fat (C) and protein (D)  
































































3.4 Baseline vs. 4 weeks – Symptoms 
3.4.1 IBS-SSS 
Table 3 presents the results from the IBS-SSS questionnaire. All individual symptom scores 
dropped during the diet, but statistically significance was only reached for “abdominal pain”, 
“abdominal distention”, “dissatisfaction with bowel habits” and “interference with life in 
general” (p=0.006, p=0.0005, p=0.009, p=0.042, respectively)(Figure 11A). The IBS-SSS 
total score is a sum score of the five main questions in the questionnaire. This score 
decreased significantly from baseline 310.2 to 171.4 at 4 weeks (Figure 11B). For most 
participants the IBS-severity grade was reduced from baseline to 4 weeks, and two of them 





Figure 11: IBS-SSS individual score of main questions (A) and total score (B) 










































Severity of abdominal pain**
Frequency of abdominal pain
Severity of abdominal distention*** 
Dissatisfaction with bowel habits**
Interference with life in general*
A B 
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Table 3: IBS-SSS: Total, individual and additional GI complaints scores 
at baseline and at 4 weeks 
 Baseline 4 weeks p-value  
IBS-SSS total score, mean ± SD 310.2 ± 60.7 171.4 ± 107.2 0.001** 
Main questions, mean ± SD 
Severity of abdominal pain 
Frequency of abdominal pain 
Severity of abdominal distention  
Dissatisfaction with bowel habits 
Interference with life in general 
 
43.5 ± 19.8 
46.4 ± 30.4 
64.7 ± 19.7 
87.4 ± 12.8 
75.6 ± 23.0 
 
22.2 ± 25.2 
22.7 ± 25.7 
15.8 ± 26.7 
58.3 ± 28.0 







Additional questions, mean ± SD 
Total score 
Nausea and/or vomiting 




Belching and/or passing gas 
Heartburn 
Frequent/sudden urge to urinate 
Pain in the thighs 
Pain in muscles and joints 
 
414.5 ± 111.9 
25.7 ± 23.4 
45.6 ± 20.2 
29.8 ± 23.0 
47.3 ± 38.5 
72.0 ± 23.4 
62.0 ± 34.7 
18.8 ± 31.5 
45.6 ± 37.7 
27.3 ± 35.2 
42.1 ± 23.4 
 
263.7 ± 164.9 
15.0 ± 18.5 
24.1 ± 23.9 
18.4 ± 22.6 
25.7 ± 31.2 
50.3 ± 29.9 
34.4 ± 27.5 
12.4 ± 24.6 
44.9 ± 33.2 
7.6 ± 14.8 

































Total IBS severity grade Severe Mild 0.001** 
Data are presented in n or mean ± SD for IBS-SSS total scores (0-500), individual scores (0-100) and 
scores of additional GI complaints (0-1000 and 0-10), P-value from unpaired t-test  







3.4.2 IBS-SSS Additional GI complaints and comorbidity symptoms score 
The total score of the additional questions in IBS-SSS showed a statistically significant 
reduction from 414.5 to 263.7 (p=0.002), reflecting improvement of symptoms (Table 3, 
Figure 12). The individual scores with a significant reduction were “nausea” (p=0.02), “early 
satiety/difficulty in finishing meals” (p=0.001), “backache” (p=0.006), “fatigue” (p=0.02), 
“belching and/or passing gas” (p=0.04) and “pain in the thighs” (p=0.04) (Figure 12). 
“Headache”, “heartburn” and “pain in muscles and joints” were improved as well, but with 















Figure 12: IBS-SSS additional questions individual scores (A) and total score (B)  
at baseline and after 4 weeks. Range of total score is 0-1000, range of individual scores are 0-100,  




























IBS-SSS Additional questions, individual symptom scores 
Nausea and/or vomiting*




Belching and/or passing gas*
Heartburn
Frequent/sudden urge to urinate
Pain in the thighs*





















Additional question total score 
**
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   Total score 
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3.4.3 IBS-SQ Grading of symptoms  
Table 4 presents the results from IBS-SQ questionnaire. The mean total score was reduced 
significantly from 27.4 to 15.7 (p=0.002) reflecting improvement of symptoms after 
converting to LFD (Figure 13). The individual symptoms with a significant decrease were 
“bloating”, “abdominal pain”, “constipation” and “diarrhea”, while the decrease in “nausea” 
was borderline significant only (Figure 13). 
 
Table 4: IBS-SQ: Total score and individual symptom scores at baseline and at 4 weeks 
 Baseline 4 weeks p-value 
IBS-SQ total score, mean ± SD 27.4 ± 4.1 15.7 ± 10.1 0.002** 
IBS-SQ individual question scores 
Nausea 
Bloating 





3.7 ± 3.3 
7.2 ± 2.0 
5.4 ± 1.5 
3.0 ± 1.8 
6.7 ± 2.8 
1.4 ± 1.7 
 
2.7 ± 3.4 
4.2 ± 3.1 
2.8 ± 3.1 
1.4 ± 1.6 
4.1 ± 3.1 








Data are presented in mean ± SD for IBS-SQ total score (0-60) and individual scores (0-10).  







Figure 13: IBS-SQ individual symptom scores and total score at baseline and at 4 weeks 


















































IBS-SQ Total score 
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3.4.4 Ad hoc questionnaire for grading of radiation injury based on RTOG  
Only 10 participants completed the Ad hoc questionnaire both before and after intervention. 
Results from the VAS graded symptoms in the scheme are presented in Table 5. All the 
typical RISBD complaints were reduced from baseline, but the improvement was only 
significant for “diarrhea”, and borderline significant for “Fecal incontinence” (Figure 14). 
 
Table 5: VAS symptom scores from Ad hoc questionnaire for grading of radiation damage  
at baseline and at 4 weeks 
 Baseline 4 weeks  p-value 
Abdominal cramps, mean ± SD (n) 46.5 ± 20.8 (8) 32.3 ± 30.7 (6) 0.146 
Rectal mucus, mean ± SD (n) 44.6 ± 14.1 (6) 22.8 ± 30.7 (4) 0.125 
Rectal bleeding, mean ± SD (n) 30.1 ± 21.6 (3) 20.2 ± 30.2 (3) 0.193 
Diarrhea, mean ± SD (n) 62.2 ± 19.7 (9) 20.2 ± 29.8 (4) 0.005** 
Constipation, n  2 1 0.343 
Fecal incontinence, times per week 5.1 ± 2.8 2.2 ± 3.5 0.053 
Data are presented in mean ± SD for VAS scores (0-100) and for times per week (0-10) for fecal 
incontinence. P-value from unpaired t-test *: p≤ 0.05, **: p≤ 0.01 
  
Figure 14: VAS symptom scores from Ad hoc questionnaire for RT damage grading  
Showing change in scores of abdominal pain (A), rectal mucus (B), rectal bleeding (C), constipation 
(D), diarrhea (E) and fecal incontinence frequency (F) at baseline and at 4 weeks 







































































































3.4.5 Use of pharmaceuticals  
The self-reported use of medications was registered. The most frequent used medication was 
Imodium® (Loperamide), an antidiarrheal drug that reduces peristaltic movement in the GI 
(84). Seven of the included participants used this drug during RT to diminish the acute 
symptoms of RISBD. Five have been using Imodium® after completing RT, either regularly 
(n=2) or only in periods when needed. Of the two participants that reported regularly usage of 
Imodium®, one used 2 mg daily and the other used 2 mg 2-3 times daily. The first-mentioned 
also reported daily use of the supplement Lectinect®, which is supposed to improve various 
GI-symptoms by the effect of the active herbal ingredient elderflower (85). During the LFD 
intervention she experimentally discontinued both drugs without reoccurrence of symptoms. 
The second participant tried to lower the dose to once daily, but without successful outcome.    
 
3.5 Baseline vs. 4 weeks – Health related quality of life  
3.5.1 SF-NDI 
Table 6: SF-NDI Total score and subscale scores at baseline and at 4 weeks  
 Baseline 4 weeks p-value 
Total score, mean ± SD 30.5 ± 9.4 18.3 ± 8.2 0.001** 
Subscale scores  
Tension 





3.2 ± 1.1 
3.2 ± 1.3 
3.5 ± 1.3 
2.6 ± 0.6 
2.7 ± 1.4 
 
1.7 ± 0.8 
1.7 ± 1.1 
2.1 ± 1.2 
2.0 ± 0.8 







Data are presented in mean ± SD for total score (0-60) for subscale scores (0-10)  
P-value from unpaired t-test *: p≤ 0.05, **: p≤ 0.01, ***: p≤ 0.001 
 
Table 6 presents the change in HRQOL scores based on the completion of SF-NDI. The 
mean total score was 18.3 after 4 weeks intervention compared to 30.5 at baseline (p=0.001). 
This reduction reflects a significant improvement of perceived quality of life. A significant 






Figure 15: SF-NDI subscale scores (A) and total score (B) at baseline and at 4 weeks 
*: p≤ 0.05, **: p≤ 0.01, ***: p≤ 0.001 
 
3.5.2 SF-12 
The responder results of SF-12 at baseline and at 4 weeks compose eight domain scores, 
which together determine a PCS score and a MCS score (Table 7). The domain scores that 
improved significantly were “role physical”, “bodily pain”, “general health”, “vitality” and 
“role emotional”, while the improvement of “social functioning” and “mental health” were 
borderline significant (Figure 16). At baseline the mean score for physical health (PCS) was 
44.1 and increased to 48.8 after 4 weeks (p=0.134). The mean score for mental health (MCS) 
showed a significant increase from 45.9 to 55.1 at 4 weeks (p=0.047)(Figure 16). The 






































































Table 7: SF-12: PCS scores, MCS scores and domain scores at baseline and at 4 weeks 
 Baseline 4 weeks p-value 
Physical component summary, mean ± SD 44.1 ± 9.0 48.8 ± 7.9 0.134 
Mental component summary, mean ± SD 45.9 ± 12.8 55.1 ± 5.1 0.047* 
8 domain scores, mean ± SD 
Physical function (PF) 
Role physical (RP) 
Bodily pain (BP) 
General health (GH) 
Vitality (VT) 
Social functioning (SF) 
Role emotional (RE)  
Mental health (MH) 
 
70.5 ± 29.2 
65.9 ± 21.0 
65.9 ± 25.7 
35.5 ± 32.1 
27.3 ± 26.1 
72.7 ± 26.1 
78.4 ± 26.9 
62.5 ± 28.5 
 
79.6 ± 27.0 
81.8 ± 15.2 
88.6 ± 13.1 
57.3 ± 33.9 
50.0 ± 22.4 
90.9 ± 16.9 
97.7 ± 5.1 










Data are presented in mean ± SD for PCM (0-100), MCS (0-100) and domain scores (0-100)  




Figure 16: SF-12: Domain scores (A), physical (B) and mental component score (C) 






























































3.6 Compliance  
3.6.1 Adherence during the intervention  
The participants seemed satisfied with the effects of the diet, and had high adherence based 
on the self-reported compliance form filled after 4 weeks, despite the fact that they reported 
the diet to be relatively challenging (Table 8). The adherence to the diet was for all but one 
participant higher than 75% and the remaining one reported a compliance of 72%. 
 
Table 8: VAS scores for adherence, satisfaction and level of difficulty following LFD 
 Mean SD 
Range of adherence to LFD through 4 weeks (0-100) 94.8 8.3 
Satisfaction with LFD on symptom relief (0-100) 89.4 16.5 
Level of difficulty in following LFD (0-100) 51.9 24.3 
Data are presented as mean and SD for VAS scores (0-100)  
 
 
3.6.2 The low FODMAP diet 
On the question regarding if they wanted to continue on the diet, eight replied “yes”, two 
replied “maybe”, and one replied “only with continuous counseling”. Deviations from the 
diet was reported as “4-6 times a week” by one, “1-5 times during 4 weeks” by seven, and 
three participants reported to have had no deviations. The amount of non-LFD foods eaten 
was for two “a whole meal”, for four “2-5 mouthfuls” and for two “one mouthful”. Most of 
those who made exceptions from the diet, reported that it happened by accident or lack of 
knowledge of ingredients (n=5). Two deviated because of lack of alternatives available 
during restaurant visit and one had craving for something else. Fructans in form of 
onion/garlic and fructose were the most frequent FODMAP groups in diet deviation. All 
patients were pleased with the information given about the diet, with two being “satisfied”, 




3.6.3 Adherence to the diet 4-6 weeks after completing intervention  
All participants filled and returned a second compliance form 4-6 weeks after the study 
period and the self-reported results from this are presented in Table 9.  
  
Table 9: VAS scores for adherence and reintroduction phase difficulty 4-6 weeks after  
completing the intervention 
 Mean SD 
Level of maintaining adherent to LFD (0-100) 65.8 27.8 
Level of difficulty in reintroducing FODMAPs (0-100)(n=9) 51.5 21.2 
Data are presented in mean and SD for VAS scores (0-100)  
 
Not all participants continued to follow LFD. Reasons for going back to their habitual diet 
were that “the diet did not give enough effect to make the effort worthy” (n=3), “there are 
only some foodstuffs that promote symptoms”(n=3), “privation for too many foodstuffs” 
(n=2) or “lack of self-discipline” (n=1). Four participants did a systematic reintroduction of 
FODMAP groups, five tried to systematic reintroduce some FODMAPs, and two went back 
to habitual diet without trying to reintroduce. The most problematic FODMAP groups 
regarding symptom onset and symptom severity reported by the participants are presented in 
Figure 17.   
 
 
Figure 17: Most problematic FODMAPs reported 4-6 weeks after completing intervention   




















































The reintroduction phase seems to be perceived relatively difficult, as the reported mean 
degree of difficulty was 51.5% whit the maximum score of 100% being equivalent to “very 
challenging”. The reported difficulties with this phase was “to know that they most probably 
would get symptoms from the food item”, “to know whether the symptoms came from that 
specific food item” and “to differentiate between normally occurring symptoms and 
symptoms arising from that specific food item”.  Four answered “yes” on the question 
regarding if they were to continue on the diet, and seven answered “partially”.  
 
3.7 Correlations 
Correlation analyses revealed no statistically significant correlations between symptoms and 
the other variables measured; HRQOL, baseline FODMAP intake and radiation dosage 
(Table 10). Only a borderline significant correlation was seen between the baseline score of 
IBS-SSS and SF-NDI.  
 
Table 10: Correlation analyses of FODMAP intake, symptoms and quality of life 
 Pearson r analysis r r2 p-value 
IBS-SSS vs. SF-NDI baseline  0.576 0.332 0.064 
IBS-SSS vs. SF-NDI 4 weeks 0.467 0.218 0.148 
IBS-SQ vs. SF-NDI baseline -0.116 0.013 0.735 
IBS-SQ vs. SF NDI 4 weeks  0.156 0.024 0.646 
FODMAP vs. IBS-SSS  -0.317 0.100 0.343 
IBS-SSS vs. Dosage 0.094 0.009 0.796 
Data are presented in Pearson correlation coefficient (r) and r-squared. P-value from Pearson 




4. DISCUSSION  
4.1 Main findings 
We conducted an open quantitative, prospective pilot study to examine the effect of a low 
FODMAP diet on patients with RISBD developed after pelvic radiation treatment against 
cancer. The intervention group consisted of 11 participants who followed LFD for 4 weeks. 
There was no control group. Dietary intake, RISBD-related symptoms and HRQOL were 
registered before and after the diet period to reveal and quantify changes.  
 
The intervention was successful in form of reduction of FODMAP intake, shown by a 3-day 
food record, together with a self-reported compliance scheme (mean adherence 94.8%). In 
addition to FODMAP intake, the subjects significantly lowered their daily total energy 
intake, their carbohydrate intake and their fiber intake (p=0.004, p=0.001 and p=0.03, 
respectively). The absolute intake of fat and protein (g/day) was reduced compatible with the 
reduction in total amount of energy consumed, but their relative contribution to the total 
calorie intake (E%) increased. The LFD accordingly seems to make a shift to less 
carbohydrate and more fat and protein in the diet. Based on self-reported weight, the 
populations mean change in body mass was -1.6 kg (p=0.006).  
 
GI-symptoms improved considerably during the intervention. The total IBS-SSS score 
decreased from mean 310.2 to 171.4 from baseline to end of intervention (p=0.001). The 
mean score was reduced for all the individual main IBS-SSS questions and this change was 
significant for “severity of abdominal pain”, “severity of abdominal distention”, 
“dissatisfaction with bowel habits” and “interference with life in general”. For the 10 
additional questions in the IBS-SSS questionnaire, the total score (mean 414.5 vs. 263.7), and 
the individual question scores for “nausea and/or vomiting”, “difficulties in finishing meals”, 
“backache”, “fatigue”, “belching” and “pain in thighs” were significantly lower after 4 weeks 
LFD compared to baseline. Significant symptom improvement was also documented by the 
IBS-SQ questionnaire (mean total score 27.4 vs. 15.7). Reported scores of bloating, 
abdominal pain, constipation and diarrhea were significantly improved on the diet. 
 
LFD seems also to enhance HRQOL for RISBD patients based on this study. The mean total 
score of the SF-NDI questionnaire decreased from 30.5 to 18.3 (p=0.001), corresponding to 
improved perceived quality of life. The improvement in scores was significant for the 
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subscales “tension”, “interference with daily activity”, “eating/drinking”, 
“knowledge/control”, and “work/study”. Results from SF-12 showed a significant increase of 
the mental (MCS) score (45.9 vs. 55.1), and a non-significant increase of the physical (PCS) 
score (44.1 vs. 48.8). Significant improvements were achieved for the domains “role 
physical”, “bodily pain”, “general health”, “vitality” and “role emotional”. Non-significant 
improvements were observed for “physical functioning”, “social functioning” and “mental 
health”.  
 
4.2 Discussion of findings  
4.2.1 Dietary intake  
From the study results, LFD seems to cause a shift to less carbohydrate and more fat and 
protein in the diet, and this tendency is also reported from previous LFD trials (86). This is an 
expected consequence because all FODMAPs are carbohydrates, but not a wanted outcome. 
The aim of the dietary counseling is to provide good information about food alternatives to 
keep the distribution between the main energy sources unchanged. The increased energy 
contribution from protein is not considered problematic, but an increased fat intake could be. 
This is based on the established opinion that excessive intake of fat, especially saturated fat, 
implies a potential negative risk for lifestyle diseases (87). In addition, RISBD patients may 
have a lower absorption capacity for fat due to bile acid malabsorption, which can lead to 
increased GI symptoms when increasing fat intake (4, 16, 88). The recommended distribution 
of energy sources is 45-60 E% from carbohydrate, 25-40 E% from fat, and 10-20 E% from 
protein (87). In the conducted study the baseline E% of fat was 36.8 and this increased to 
38.4 at 4 weeks. Carbohydrate changed from 46.5 E% to 42 E% and protein from 17.4 E% to 
19.3 E%. This shows that despite the increase in energy proportion from fat, the distribution 
is still in line with the general recommendation. Based on the amount in gram, the fat intake 
was not at all excessive, nor risk promoting, during LFD.   
Besides being the largest contributor to energy, carbohydrates have other important roles in 
the diet. In the traditional Norwegian eating habits, most meals are based on this source in 
form of different variants of bread, cereals and also as a side dish for supper. Foods high in 
carbohydrates have a good filling capability and provide fiber to the diet. Fiber should be 
included in a healthy diet because it promotes healthy bowel function and also serves as 
nutriment for a favorable microbiota. Based on this, the Norwegian Directorate of Health has 
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set a daily recommendation for dietary fiber intake of 25-35 g/day (87). This is above both 
the reported baseline and at 4 weeks mean intake of fiber in the study population, which was 
18.8 g/day and 13.9 g/day, respectively. Regarding the effect LFD has on microbiota, this is 
currently a research topic of high interest. No firm conclusions are made, but it seems as if 
the diet could have a negative long-term effect on the composition and function of microbiota 
(55, 56, 61, 64, 65, 89).  
 
The amount of calcium was registered from the food records before and after intervention. 
The reason for this interest is that dairy products, which are the main diet source for calcium, 
often contain lactose that needs to be excluded on LFD. Therefore, there is a possible risk for 
a decreased and inadequate intake of this micronutrient. The recommended daily intake is 
800 mg/day for the study populations sex and age group (87). According to the food records, 
the mean intake of calcium was below this recommendation both at baseline and during the 
diet intervention. While the mean intake decreased with about 100 mg/day (p=0.332), the 
majority of the participants (n=6) actually increased their intake of calcium on LFD.  The 
reason why the calcium intake overall remained relatively stable, is probably the wide 
selection of lactose free and lactose reduced dairy products on the Norwegian marked.  
 
The mean change of weight during four weeks on LFD was a reduction of about 1.6 kg. 
About all subjects lost weight, and only one gained 1 kg, from baseline to end of intervention. 
This is consistent with the reduction in mean energy intake and is reported also from other 
LFD studies (90, 91). An interesting observation was that the only subject who increased the 
intake of calories was also the one who lost most body mass (5 kg). Simultaneously, the only 
participant who gained weight still had decreased her daily energy intake (about 100 kcal). 
The explanation for these findings is most likely that the food records filled during only three 
days did not capture a representative picture of the actual dietary intake for the whole period 
of four weeks. This is a known weakness of methods assessing dietary intake (67, 92). An 
alternative possible explanation could be that the reduced intake of energy (and also 
FODMAP), lead to less symptoms and less diarrhea, promoting an improvement in uptake 
and utilization of the calories consumed.  
The participants reported their body mass themselves by writing both weight and height on 
the first page of the food records. This limits the reliability of the registration, as self-reported 
weight implies a high bias risk (93). There was no assurance that the written weight was the 
subjects’ actual weight, and that it was measured recently not only a report of what they use 
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to weigh. If the values actually are correct, the resulting mean weight loss is an interesting 
but undesirable effect of LFD. The wanted effect is a relief in symptoms and improved 
HRQOL, not a reduction in weight. The diet should provide good alternatives so that 
adequate amounts of energy, macro- and micronutrients are consumed. This emphasizes the 
importance of comprehensive counseling by preferably a registered dietitian (94).  
Noteworthy, some of the participant expressed a want for a weight reduction, and may have 
used the diet for this purpose in addition to the IBS symptom response. The negative noted 
side effects on intake of energy, dietary fiber and weight change, denotes skepticism about 
the safety of eating LFD over time. The diet is possibly not accurate to meet the basic dietary 
needs, neither in line with a diet that diminishes the risk for lifestyle diseases and promotes a 
healthy GI bacterial flora.  
4.2.2 FODMAP intake 
The study only included patients who were not already following the low FODMAP diet. 
Yet, some participants had heard of it, and some had already excluded various foodstuffs and 
drinks based on self-experienced correlation between food intake and symptom onset. Many 
of these foodstuffs were FODMAP containing (such as wheat, dairy products and onion). All 
subjects were encouraged to eat a “regular” diet from recruitment until start of diet period, 
and hence include the problematic food they had excluded. This was necessary to diminish 
the risk that restrictions at baseline could mask the effect of the intervention. Based on the 
baseline food records, it seems like the participants did re-include problematic foods in prior 
to the start of the diet period.  
The participants mean intake of FODMAP at baseline was 22 g/day. The mean FODMAP 
intake in the Norwegian population in general is unknown, but in a recent study the 
FODMAP content of a regular Australian diet was found to contain 23.7 g/day (95). Magge 
et al. defined 9 g of FODMAP per day as low, and 50 g/day as high (96). Former similar 
studies conducted by master students at UiB reported baseline daily FODMAP intakes for 
their study populations of 19.2 g, 13 g and 6.3 g, respectively (the last one being a gluten free 
diet) (65, 97, 98). In the original description of LFD, a food item is high in FODMAP if it 
contains >3 g fructose per meal, >0.2 g fructans + galactans per meal or >0.5 g polyols per 
meal (54). Based on this, the baseline FODMAP intake in the present study seems relatively 
normal, being neither extraordinary high, nor low. The FODMAP group that contributed 
most to the total amount was the disaccharide lactose, whit a baseline mean of 10 g/day. The 
threshold value per meal for this FODMAP group is not given in the description. 
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Interestingly Suarez et al. found that up to two cups of milk (equals around 16 g lactose) per 
day can be tolerated by lactose intolerant individuals if it is divided over several meals (99). 
The prevalence of lactose malabsorption in the western population is low, and not found to be 
more prominent in IBS patients (100). The participant with the lowest reported adherence to 
LFD also had minimal improvements in symptoms (260 to 235 points in IBS-SSS score). Her 
FODMAP intake at 4 weeks was 9.2 g/day, which is an amount just above what is defined as 
low FODMAP (<9g). Her intake of lactose was 6.7 g/day, which is a notable but not a very 
high amount if it is spread over several meals, based on the findings from Suarez et al. Her 
lack of symptom improvement could thus be due to her LFD deviations, but this is not 
unambiguous.  
 
No significant correlation was found between the baseline intake of FODMAP and the 
severity of IBS symptoms (IBS-SSS total score) based on Pearson r two-tailed correlation 
analysis (p=0.340). The participant that had the highest amount of FODMAP intake (50 
g/day) also had one of the lowest IBS-SSS total scores at baseline (258 points). The one with 
the highest score on IBS-SSS (420 points) had a FODMAP intake around the average for the 
study population (21.1 g/day). This reflects the multifactorial situation in the symptom 
picture of this disease. It can also be a result of a large intra-individual variation of FODMAP 
intake and symptom severity from day to day. Neither a 3-day food record, nor the 
registration of symptoms at only two time points is enough to uncover this variation.  
4.2.3 Symptoms 
Information about the received RT was obtained from the participant’s medical record at the 
respective hospitals, for 10 of the 11 participants. Mean dosage received was 63.7 Gy. During 
the diagnostically evaluation of a new cancer case, a FIGO stadium (The International 
Federation of Gynecology and Obstetrics) is determined. Stadium I is often treated only with 
surgery, while stadium II-IV are treated with radiation with or without combined 
chemotherapy (13). In the study population four had stadium I, four had stadium II, one had 
stadium IV and for the last two these data were not found. There was no correlation between 
radiation dosage and severity of IBS symptoms at baseline (based on IBS-SSS). However, the 
low number of patients, variable radiation dosages and co-treatments, as well as uncertainties 
about disease stages, limit the reliability of correlation analyses. Multiple factors influence 
the development of chronic RISBD, and longitudinal studies of larger and homogenous 
patent groups are required. 
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The mean decrease of IBS-SSS of about 139 is far above the cut-off value of 50 points that is 
considered successful treatment response, and the change is equivalent to an improvement of 
mean IBS-grade from severe to mild. Based on the severity grading of IBS, two participants 
achieved remission of their GI symptoms (IBS-SSS score <75) (75). The improvements seen 
in “diarrhea”, “abdominal pain” and “dissatisfaction of bowel habits” is not surprising. These 
symptoms are all part of the diagnostic criteria for IBS, and because of LFD’s known effect 
for IBS, the improvement could be anticipated. But in the two symptom-questionnaires all 
symptoms were reduced, including comorbidity symptoms. This includes “nausea”, 
“vomiting”, “early satiety”, “headache”, “backache”, “tiredness”, “heartburn”, “urge to 
urinate” and “pain in tights and muscles”. Some of these can indirectly be linked to IBS-
criteria symptoms, but some are unrelated to them. The reason for the result on non-GI and 
upper-GI symptoms is not known, but similar observations have been seen in studies on the 
effect of LFD for IBS (65, 101, 102).  
The two questionnaires used to register symptoms were overlapping as they both graded 
abdominal pain, bloating and nausea (either as a VAS-score or as a numeric scale from 1 to 
10). The first two of these symptoms were significantly reduced according to both IBS-SSS 
and IBS-SQ, but that was not the case for nausea. Both schemes registered a reduction in 
nausea (mean 25.7 to 15.0 and 3.7 to 2.7), but this was only significant in IBS-SSS. Because 
of these not throughout significant findings, it is difficult to make a conclusion on the effect 
LFD has on the severity of nausea. This inconsistent finding between the questionnaires used 
in the study, can also elucidate a reason for doubt on the suitability of using these exact 
questionnaires for this purpose. On the other hand, nausea is not the most prominent 
symptom in this patient group, having a mean of 25.7 of 100 and 3.7 of 10 at baseline, and 
therefore is less sensitive for change. The low number of participants, the wording of the 
questions asked, and also the scales used, probably affects the results. Therefor, a lack of 
significant reduction based on SF-SQ is maybe not that substantial.  
4.2.4 Responders vs. non-responders 
Three study participants had a lower decrease in IBS-SSS total score than 50 points, and this 
defines them as non-responders based on this questionnaire. Published papers on LFD 
suggest that non-responders should be investigated on the basis of adherence to the diet, and 
that possible “hidden sources” of FODMAPs in their diet should be revealed. If compliance 
to the diet was good, but symptoms still persist, the attention should be focused on other 
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factors in the diet that can provide the same complaints. This could be excessive intake of 
resistant starch, insoluble fiber, caffeine or fat, or an unfavorable meal size or rhythm (55).   
 
Adherence to the diet during the 4 weeks of intervention is crucial to achieve an effect on 
both symptoms and HRQOL. The grade of compliance for the three non-respondents was 
relatively high, but varied. One of them reported an adherence of 100%, one of 90%, and the 
last one had an adherence of only 72%. The latter had a moderate intake of lactose during the 
LFD period in form of eating brown cheese almost daily for breakfast. This is possibly a 
contributing factor for her failing symptom relief. In addition to this she consumed both apple 
and orange juice during the intervention period resulting in a estimated mean FODMAP 
intake at 4 weeks of 9.2 g/day (e.g. above the limit of 9 g/day) (96). This participant also had 
the lowest intake of calories, which was as low as 958 kcal/day at baseline and surprisingly 
low, 504 kcal/day on LFD. This amount is far below the recommended intake for her age and 
gender of about 2000 kcal/day based on estimations from Kostholdsplanleggeren.no. Based 
on these findings, this particular patient should perhaps be considered an extraordinary case, 
which presents with dissimilarities to the other included participants. Statistical analyses 
excluding data from this patient should perhaps have been done.  
 
If the subjects still consume high amounts of fiber, this may explain the lacking/insufficient 
effect of LFD. Coia et al. suggests that a low-residue diet can limit the symptoms (53, 103). 
The low FODMAP diet is not necessary in accordance with that. The Norwegian 
recommendation for daily fiber intake is 25-35 g/day. The study populations mean daily 
intake at baseline was 18.8 g, and was reduced to 13.9 g during the LFD period. The group’s 
intake of fiber was accordingly beneath the recommended amount both before and after the 
intervention. The individual intakes for the subjects who did not have successful symptom 
reduction, showed no correlation with the fiber intake. The three subjects in this group had 
baseline daily fiber intake of 14.3 g, 27.5 g and 17.3 g, respectively. They all reduced their 
intake to 12.2 g, 14.7 g and 5.4 g, respectively.  
 
Fat intake can be related to response effect in symptoms. The traditional advises given to 
patients at risk for RISBD include reduction and distribution of the daily fat intake. This 
recommendation is based on the fact that bile acid absorption can be affected after small 
bowel damage and that this can provoke diarrhea if the fat load to GI is high (4, 88). It is 
expected that the intake of fat could increase on LFD because of the restriction in 
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carbohydrates. Again looking at the three non-respondents, their fat intake at baseline 
contributed to 28%, 32% and 29% of their total energy intake. This is for all of them in line 
with the government’s recommendation of 25-40% of energy coming from fat (87). Their 
intake changed respectively to 27 E%, 30 E% and 38% on the LFD. The absolute change in 
fat intake in grams for these three participants was from 41.2 to 35.2, from 70 to 62.7 and 
from 31.3 to 21.6, respectively. The fat load to the GI lumen accordingly decreased rather 
than increased when looking at the absolute amount consumed. Based on these numbers, 
intake of fat is most likely not the cause of the lacking symptom relief.  
4.2.5 Health related quality of life 
Based on SF-NDI and SF-12 the participants’ perceived HRQOL improved. These findings 
are highly important to report, since RISBD is known as a disease that strongly affects 
quality of life (2). Independent of which kind of symptoms that alleviate, the fact that the life 
quality for patients improved is an effect that is highly appreciated. Fecal incontinence is 
considered to be the symptom that most prominently influences RISBD patients quality of 
life (11). This was supported by the results of this study. The three patients with the strongest 
reduction in total score of SF-NDI (reductions of 22-25 points) all had scored their frequency 
of fecal incontinence to zero times per week at the study endpoint (baseline scores was 5, 6 
and 7 times of maximal score of 10).  
4.2.6 Relationship between symptom relief and improvement in quality of life 
A significant improvement was found in both RISBD-related symptoms and perceived 
quality of life. These findings suggest that GI symptoms affect HRQOL and/or visa versa. 
Still, this does not prove that these two variables are directly correlated. For example, the 
participant with the highest score in SF-NDI (i.e. worse HRQOL) at baseline (45 points) had 
only the sixth highest score in IBS-SSS (339 points). Simultaneously the one with highest 
total score in IBS-SSS (420 points) had only the sixth highest score in SF-NDI. The same 
was seen at 4 weeks where the one with the highest score in SF-NDI had the third highest in 
IBS-SSS, and the highest in IBS-SSS had the third highest in SF-NDI. This trend is 
supported by correlation analyses conducted, which did not show significant results, neither 
at baseline nor at 4 weeks. An explanation for this discrepancy between symptom relief and 
improvement in HRQOL is perhaps that many other factors affect quality of life, and that 
these are expected to change during a period of 4 weeks.  
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4.2.7 Patient experiences 
The participants found it quite challenging to follow LFD. The mean level of difficulty score 
was about 52 of maximum 100. This score varied considerably between the participants, as 
the lowest score was 9.5 and the highest was 79. Looking at the individual scores, it seems as 
those who found the diet undemanding, were the same ones who had larger difference in 
IBS-SSS scores between baseline and 4 weeks. The four subjects that found the diet most 
difficult (over 60%) also had the lowest difference in IBS-SSS score (around 100 or less). 
This relation was supported by a significant correlation analysis between “level of difficulty 
following LFD” and the difference in IBS-SSS total score (from baseline to 4 weeks) with a 
Pearson r of -0.7 (p=0.018)(results not shown). The cause/effect relation between these two 
variables is not known. It could be that those finding the diet easy to follow consequently 
have better adherence, which gives better effect. It could also be that those who feel symptom 
relief get higher motivation and therefore find it easier to follow the strict diet. 
 
In addition to the measurable effects presented, the participants’ overall satisfaction 
communicated orally is very pleasing. Some of the subjects have described the diet as “life-
changing” for them, and that adapting to LFD has opened new possibilities for them. Many 
subjects felt isolated and homebound because of their need of always having a toilet within 
reach, because of incontrollable fecal urge. The master student experienced examples of this 
when participants were forced to hang up on the phone suddenly during the diet counseling to 
find the nearest toilet. Many have reported more control over this problem after 
implementing LFD. One patient, who earlier had to quit her job, was one month after the end 
of study back working full time. Some also report that they to a greater extent dare to join 
social events than before implementing LFD. On the other hand, others found social events 
more challenging to attend on the diet, especially during the first weeks of the strict diet 
period. Reason for this is that they were uncertain of what to eat and not to eat, and the need 
to pre-plan meals away from home. The feeling of being a burden to the one inviting them for 
a meal is also not unusual. This corresponds to the lack of significant improvement of the SF-
12 domain “social functioning”. This aspect of LFD being both an advantage and a 
disadvantage in social settings is probably varying over time. When the participant gradually 
are becoming more certain of what they can eat and not, and get known with their tolerable 
limits of foodstuffs, hopefully the diet becomes more an advantage.  
Another challenge reported during the study, was to eat enough and the feeling of hunger. 
Some subjects contacted the master student during the first weeks, because they needed 
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extended counseling and help finding low FODMAP alternatives. Most of them struggled 
with finding good alternatives for between-meal-snacks, but also alternatives to bread and 
crisp bread.  
Noteworthy, the registration of weight change did not differentiate between intended and 
unintended weight loss, and several participants expressed satisfaction with having lost some 
kilos.  
 
4.3 Study limitations 
4.3.1 Recruitment 
The methods for recruiting patients to the study present some possible risks of bias. First of 
all there is a limitation in the fact that the study was open and that a lot of the participants 
contacted the master student by their own initiative through information shared on Internet. 
This presents a risk for the group of participants to be more motivated to follow a diet like 
LFD, and that the type or severity of symptoms differs from the patient group in general. This 
method of recruitment only reaches out to patients that are active on Internet and social 
media, and therefore looses the ones that don’t seek these platforms. Internet activity is also 
most likely related to age and gender.  
Secondly, the fact that the recruitment of most of the participants did not go through referral 
from clinicians either at HMU, the Department of Medicine or the Department of 
Gynecology, as we initially intended, makes the information about the extent and type of 
radiation damage limited. Although we ensured that all participant had received pelvic RT in 
the past and that the symptoms arised in aftermath, it is possible that some of them suffered 
from regular IBS not related to their cancer treatment. This bias could have been diminished 
if the inclusion criteria had required that a full gastroenterological examination needed to 
have been conducted before recruitment. Still, this would have made the recruitment more 
challenging, more resource demanding and beyond the scale of this project.  
 
Pre-inclusion efforts to adapt to the low FODMAP diet did not lead to exclusion from the 
study and some participants reported to have tried the diet before. Individuals in this situation 
may have had a better understanding and motivation to adapt to LFD, and therefore have 
been more likely to comply with the diet and consequently respond positively. This risk is 
especially present if the former attempt was by own initiative.  
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The recruitment process could have been better planned and more systematically carried out. 
The way of getting in touch with the patient group was in many ways generated concurrent 
with the recruitment. New channels to spread the information came up during the entire 
recruitment period, also after suggestions from already included participants. As a result, 
some potentially valuable sources for new participants were discovered too late regarding the 
limited duration of the recruitment phase. By protocol, the desirable number of subjects was 
18. This number was set based on the number of patients with GI-complaints referred to the 
HMU the past years, combined with the number of patients needed for statistical power of the 
hypothesis tests. Still, we did not want more than 18 subjects because of the fact that the 
study was a pilot study. It would have been unethical to include a high sample size when the 
diet is known to be demanding and the effects unclear. The resulting number of 11 subjects is 
lower than wanted, but was still sufficient to draw statistically conclusions on the effect of 
the diet on symptoms and HRQOL.  
 
4.3.2 Demography  
The study only included female subjects. In the literature, RISBD is described as a prominent 
late effect also after treatment of prostate cancer (10), and we expected to include some male 
participants. Still there were almost exclusively women that expressed interest to join the 
study. In the recruitment phase, there was only one male patient that made contact and 
requested more information about the study. In addition, two male candidates were contacted 
through the waiting list at HMU. After receiving a brief description of the diet, all three 
considered it too demanding and therefor abstained from joining the study. Because they 
were referred to HBO, which is known to be a successful treatment, the motivation to try a 
new and strict diet in prior to their planned treatment, might have been diminished.  
The explanation for the gender discrepancy in interest for the study is probably multifactorial. 
First of all, the recruitment method using web pages and Facebook may have reached out to 
more female patients, as they might be more active on these platforms. Second, the fact that 
the intervention was a diet can attract more females based on a hypothesis that women are 
more interested and engaged in nutrition and food. Third, and the desirable true reason, is that 
more women suffer RISBD than men after pelvic RT. This could be a fact because the 
location of prostate cancer is more proximal to the small bowel than gynecological cancers, 
and because of the new methods used to radiate prostate cancer tumors. The new methods are 
 61 
considered to be more precise and consequently affect the surrounding normal tissue in a 
lesser extent, presenting lower risks of RISBD (104, 105).   
 
The mean BMI was 27.7 kg/m2, ranging from 19.6 to 39.7. BMI is a measure used to 
categorize individuals as underweight (<18 kg/m2), normal weight (18,5-25 kg/m2), 
overweight (25-30 kg/m2) or obese (>30 kg/m2) (106). The study population’s mean BMI 
corresponds to overweight, five individuals had normal weight and none of the subjects was 
underweight. Based on former published papers describing RISBD, it was expected to have a 
study population with an overall lower BMI (39). The fact that most participants were in the 
upper stratum of BMI could be an indication of having an unrepresentative patient-selection 
in the study. Having some kilos in excess can also make the participants more likely to join a 
project that involves a diet.  
4.3.3 Data collection 
4.3.3.1 Food records and calculation of FODMAP intake 
Food intake was registered both in prior to and during the LFD period, using a self-
administered 3-day food record continuously filled by the participants. This is a validated and 
frequently used method, but can be vulnerable for both over- and under reporting of intake 
(67). The fact that one participant who gained weight simultaneously seemed to have 
decreased her energy intake exemplifies this.  
The method used to calculate the consumed amount of FODMAP at baseline also implies a 
number of bias risks. Many foodstuffs are registered as FODMAP sources in the Dietist Net 
database, but not all. Therefore, for several meals/foods the FODMAP content had to be 
estimated from the ingredient list and by use of published analysis, databases and knowledge. 
This may have been imprecise, and could also have contributed to relatively large variations 
in the estimated baseline FODMAP intakes. In addition, the participants were included 
continuously and the calculation of their baseline FODMAP intake was not performed all at 
the same time. During the months the inclusion lasted, the master student may have improved 
the skills in identifying and calculating FODMAP contents. Therefore, there is a possibility 
that the intake was measured more accurate for the last participant, then the first.  
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4.3.3.2 Effect measurement  
The effects of the study were without exception measured by questionnaires. This presents a 
response bias, as the completion of questionnaires can be affected by many factors (107). The 
method is also very subjective and vulnerable to affection from the placebo effect. 
Participants may think they know the wanted outcome of the study, and answer the 
questionnaires thereafter. Other factors that can vary substantially and therefore affect the 
outcome are the time allocated to fill the questionnaire, participants memory, the order of 
different questionnaires (response fatigue), the opportunity to ask follow-up questions, 
embarrassment, the wish to succeed and the mood of the subject (107). The fact that it was a 
pilot study provides additional risk of response bias. Most participants made contact 
unprompted, and seemed very pleased to have the opportunity to join the study. This can 
have lead to patients feeling indebted to the master student, and consequently completed the 
forms in a way that favored a positive outcome.   
Two different questionnaires were used both to measure symptoms (IBS-SSS and IBS-SQ) 
and HRQOL (SF-NDI and SF-12). The reason for using both schemes was the uncertainty of 
which one of those was most suitable to reveal the effect for this exact patient group. The 
questionnaires are in many ways overlapping, but still measure some different aspects of GI 
symptoms and quality of life. Correlation analyses were done for IBS-SSS vs. IBS-SQ and 
for SF-NDI vs. SF-12 both at baseline and at 4 weeks. The symptom questionnaires had a 
positive correlation at 4 weeks (p=0.004), but no further correlations were found. This 
indicates that the questionnaires have limited overlap and their combination may be useful to 
capture a wider aspect of the symptom picture and HRQOL.  
 
4.3.4 Diet counseling  
Low response in the recruitment phase, lead to inclusion of participants from all parts of 
Norway. This resulted in that most of the diet counseling was done by phone, which made the 
standardization of the information given challenging. When not being able to use body 
language, pictures etc., the phoned counseling possibly held a lower quality then the ones 
given face-to-face. In addition, the participants were included and set to start the diet period 
in a continuing manner as they got in touch with the study coordinator. This can have led to a 
development in the way of providing the information over time, so that the first participants 
received the counseling in a different way compared to the last ones.  
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Some participants got their counseling only one or a few days before the diet was to be 
implemented. This is a short time to prepare for a quite complicated diet. The time between 
counseling and diet start was attempted to be held constant, normally getting information on 
Thursday and starting the diet period on Monday. This was not always possible to overhold. 
However, as the symptoms were not measured until 4 weeks later, needing some days to get 
used to the diet should not influence the results notably.   
4.3.5 Compliance  
During the study compliance was only registered at the end of the diet period. This presents a 
limitation, as bad compliance could not be corrected by the study coordinator in form of 
providing additional counseling and motivation for better adherence to the diet. On the other 
hand, in an actual clinical situation, close monitoring of patients is usually not possible. 
Therefore the results of the study are possible to generalize to a realistic setting.  
 
Being part of a clinical study, with a need to fill out forms and food records can give a false 
effect of the LFD caused by higher motivation and adherence. The expectations of 
improvement may also be greater in a scientific situation compared to a clinical setting after 
only one consultation. This can result in a significant placebo effect on improvement of 
symptom control and HRQOL. Since the study did not include a control group, the placebo 
effect cannot be assessed closer. This is a major weakness of the study, especially because 
this effect is known to be prominent in IBS patients on LFD. A meta-analysis with 45 
placebo-controlled RCT’s reported a placebo response of 40.2% (108). 
4.3.6 Safety 
Since most of the participants made contact by own initiative, and lived far away from the 
study center, no medical examinations was conducted. Only two participants lived close 
enough to meet in person. According to the Royal Marsden Hospital (RMH) algorithm all 
RISBD-patients with prominent GI symptoms should have a holistic assessment to exclude 
recurrent cancer and other treatable causes for their symptoms. This is especially important if 
the symptom picture includes bleeding and/or has major impact on quality of life (29, 109). 
In the conducted pilot study, no examinations like endoscopy, ultrasound, blood test or breath 
test were conducted. The study itself did thus not ensure optimized care beyond what was 
already established for the individuals.  
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It seems as LFD poses a risk for inadequate intake of energy, fiber, macro- and 
micronutrients, and can possibly change the composition and functioning of the GI bacteria 
flora over time. These factors contribute to the fact that the conduction of this study was not 
completely without safety concerns.  
 
4.4 Future aspects  
To define this patient group by providing an understanding of the pathophysiology, identify 
criteria for dietary intervention, and develop suitable diets, requires further investigation. The 
relation between RISBD and IBS is intriguing both clinically and scientifically.  
 
Based on the positive results of this small-scaled pilot study, more investigation on the effect 
of LFD for this patient group should be conducted. There is a need for controlled studies 
including patients with an ensured diagnosis of RISBD, preferably after endoscopic and 
histological examinations. Objective measurement should also be conducted before and after 
implementing LFD to reveal effects on symptoms and HRQOL. As a gold standard in clinical 
research, randomized double-blinded placebo-controlled studies are required for final 
conclusion about the effect of LFD intervention. This is a challenging approach when it 
comes to dietetic interventions. A possible approach would be to give a supplement of either 
high FODMAP or no FODMAP to two groups already following LFD. This has been 
conducted on IBS patients and can uncover if the reported effects are merely due to the 
placebo effect (65). There is also a need for studies with higher sample size to improve 
statistical power, as well as studies including both genders. 
 
It is not known which of the FODMAP components are most symptom promoting for this 
group of patients. Further knowledge about this could simplify the dietary advises.  
 
Finally, longitudinal studies are needed because of the safety concerns related to following a 
strict LFD over time. Insufficient consumption of energy or micronutrients, and reduced 
amount of prebiotical substances are risk factors. Baseline status and the influence of LFD on 
intestinal microbiota, mucosal microstructure and motility as well as safety and feasibility 
should be investigated. Such studies should include a substantially higher number of patients, 




Our findings establish that the low FODMAP diet seems effective in alleviating IBS 
symptoms in patients with RISBD, and that it improves their HRQOL. Typical IBS 
symptoms (e.g. diarrhea, constipation, bloating and abdominal pain) improved significantly 
after 4 weeks of LFD, and several comorbidities (e.g. nausea, early satiety, headache, 
backache, fatigue and muscle pain) were also alleviated. Clinical complaints typical for 
RISBD patients improved in a consistently but non-significantly manner. The participants 
reported improved perceived quality of life after converting to the diet. This seemed to be 
more prominent for mental aspects of HRQOL, then of physical aspects.  
 
Our results also suggest that high compliance to LFD is possible with adequate diet 
counseling and continuous guidance. Despite finding it challenging to follow, the majority of 
participants was adherent to the strict diet. They also reported to be content during the 
intervention and most of them wanted to continue after ending the trial.  
 
There are some concerns in following a strict LFD over time, because of a possible reduction 
in weight, energy intake, intake of important micronutrients and the unknown effect on 
microbiota. More research in form of controlled studies with larger samples is needed so that 
clinicians can consider implementation of the LFD as an efficacious management strategy for 
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Appendix 3: 3-day food record registration
Slik går du frem: 
 
For at vi skal kunne beregne næringsstoffinntaket ditt så nøyaktig som mulig, er det nødvendig at 
du noterer alt du spiser og drikker i løpet av en 3 dagers sammenhengende periode. Perioden 
torsdag til lørdag (evt. søndag til tirsdag) er best, for da får du med én helgedag. 
 
Det er vesentlig at du spiser slik som du pleier i registreringsperioden. 
 
• Angi klokkeslett for hver gang du spiser eller drikker noe.  
 
• Beskriv mat og drikke så nøyaktig som mulig 
 - Brød: Type, navn, grovhet, tykkelse på skiver, antall skiver. Ev. rundstykke, knekkebrød.. 
 - Fett på brødet: Type, navn, mengde, lett eller vanlig 
 - Pålegg: Type, mengde, produktnavn, lett eller vanlig  
 - Middag: Type kjøtt, fisk, kjøttfarse-/fiskeprodukt. Produktnavn. Fettprosent. 
 - Frukt og grønnsaker: Rå, kokt eller hermetisk.  
 
• Beskriv hvordan maten er tilberedt. 
- Kokt, bakt, stekt, grillet eller varmet i mikrobølgeovn 
 - Er maten er renset for skinn og/eller fett? 
 
• Hjemmelagede matretter beskrives i detalj, gjerne ved å skrive ned oppskriften bak på arket. 
 
• Notér alt tilbehør, som saus, pickles, rømme, dressing eller krem, med navn/produsent. Oppgi 
også om du bruker sukker på gryn, grøt eller i te.  
 
• Få med alle mellommåltider, samt tilfeldig spising og drikke utenom de faste måltidene.  
 
• Kosttilskudd, som tran, vitamintabletter o.l. skal også noteres, med navn, produsent og mengde. 
 
• Mengder kan beskrives på følgende måte: 
 - aller helst skal du veie maten og føre mengden opp i gram 
 - hvis du ikke kan veie, kan du angi mengder i husholdningsmål, som   
   spiseskje, glass, desiliter eller antall, alt ettersom hva som er hensiktsmessig  
- oppgi størrelse på glassene du bruker i dl 
 
Eksempel: 
Kl Tirs dag 14 / 1 / 11 Produktnavn/Produsent Vekt  
0730 1 butikkskåret skive kneip Bakers 30g 
 m/ skrapet lag margarin Soft Soya  
 3 høvelskiver hvitost, 16% fett Norvegia, Tine  
 1 stor grapefrukt  200g 
 1 stort glass lettmelk (Stort glass = 2 dl) Tine  
1100 1 beger fruktyoghurt Yoplait Dobbel 0%, mango 125g 
 1 melkesjokolade  Freia 100g 
 1 kopp svart kaffe  150g 
1500  kokt torsk  140g 
 3 små potete, kokt  150g 
 3 toppede ss revet gulrot   
 1 ss remulade Idun  
 2 store glass saft Lerum uten tilsatt sukker  
 
Kl ...... dag  ... / ... / ... Produktnavn/Produsent Vekt 
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En kostveiledning i forbindelse med diettstudie for 
























Først og fremst en stor takk til deg som ønsker å delta i studien ”Effekt av lav 
FODMAP-diett ved stråleskadet tarm”. Dette er et informasjonsskriv til deg 
bestående av litt teoretisk bakgrunn kombinert med en beskrivelse av hvordan 
dietten utføres i praksis og en matvareliste. Ikke nøl med å ta kontakt på mail eller 







Trine Larsen – Masterstudent i klinisk ernæring 
E-post: trine.L@student.uib.no 
Telefon: 970 13 209 
Appendix 4: FODMAP booklet
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IRRITABEL TARM ETTER STRÅLESKADE  
Irritabel tarm, eller irritable bowel syndrome (IBS), er ikke en sykdom, men en 
tilstand som kan medføre ulike plager i mage og tarm. Man kan oppleve symptomer 
som kvalme, mageknip, magesmerter, magekramper, oppblåsthet, utspilt mage, 
luft/gass og rumling i tarmen. Man kan også ha avføringsforstyrrelser som akutt 
avføringstrang, diaré, forstoppelse og vekslende løs/hard avføring. Som regel er det 
ikke kjent hva som er årsaken til disse symptomene, men IBS-symptomer har vist 
seg å være en vanlig akutt og kronisk bivirkning av strålebehandling mot kreft i buk-
regionen. Årsaken til dette er at vevsforandringer etter strålebehandlingen kan 
medføre at tarmen får svekket opptak av næringsstoff, blir overfølsom for gass og 
utvidelse, får endret tarmbakterieflora og/eller endret bevegelsesmønster i 
tarmveggen. For noen kan plagene utløses eller forverres av mat eller drikkke. Å 
endre på kosten kan være en god symptomlindrende behandling når man har 
stråleskadet tarm, men vil ikke fjerne årsaken til symptomene (vevsforandringen i 
tarmveggen).  
 
Generelle råd ved stråleskadet tarm  
Siden tarmveggen er skadet av strålebehandlingen vil dette kunne føre til at 
absorpsjonen (opptaket) av næringsstoffer i tarmen reduseres. Dette påvirker noen 
næringsstoffer mer enn andre. De generelle kostrådene ved stråleskadet tarm er 
basert på prinsipper om å redusere inntak av laktose, fett, gassdannende matvarer, 
sterkt krydder, hard stekeskorpe, samt å spise små, hyppige og regelmessige 
måltider. Disse rådene er generelle og passer kanskje for noen, men ikke for alle. 
Prinsippene har noen likhetstrekk i det man ser i en FODMAP-redusert kost, men 
”tillater” mange matvarer som inneholder FODMAPs. Det er en erfaring hos kliniske 
ernæringsfysiologer at lavFODMAP-dietten kan gi symptomlindring hos pasienter 
med stråleskadet tarm.  
 
HVA ER FODMAP? 
FODMAP er en forkortelse for fermenterbare oligosakkarider, disakkarider, 
monosakkarider og (and) polyoler. Dette er karbohydrater som regnes som 
tungtfordøyelige siden tynntarmen kan ha vanskeligheter med å bryte ned og 
absorbere dem. De havner derfor ufordøyd i tykktarmen hvor de tiltrekker væske (fra 
blodet til tarmen) og fermenteres (gjæres) av bakterier. Fermentering betyr at 
bakterier omdanner ufordøyd mat til gass og til energi (korte fettsyrer). Et stort inntak 
av tungtfordøyelige karbohydrater vil altså gi økt mengde væske, gass og fettsyrer i 
tarmen Dette er en normal og viktig prosess, og det er blant annet essensielt for 
tarmcellenes helse. Fermentering er noe som i ulik grad skjer hos alle mennesker, 
men de med irritabel tarm får mer uttalte plager og plager ved mindre mengder 
FODMAPs enn andre. Tanken ved lav-FODMAP dietten er å redusere inntak av 
karbohydrater som kan fermenteres i tarmen, og på den måten minske plagene. 
Dietten er utarbeidet av australske forskere (Peter Gibson og Sue Shepherd) ved 
Monash Universitet, og den er utprøvd i mange store studier, med positive resultater.  
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Hvorfor reagerer noen mer på FODMAPs enn andre?  
 
 
SLIK GÅR DU FREM 
Når man skal prøve ut FODMAP-redusert diett snakker man om to faser. Den første 
fasen er restriksjonsfasen hvor man unngår/begrenser inntaket av matvarer med 
høyt FODMAP-innhold i 4 uker. Om man ikke merker bedring etter disse 4 ukene, er 
det ingen hensikt i å fortsette med dietten. Om plagene blir mindre, derimot, kan man 
gå videre til den ande fasen som kalles reintroduksjonsfasen. I denne fasen forsøker 
man på en systematisk måte å reintrodusere de matvarene man har fjernet fra 
kosten. Man innfører en og en av undergruppene av FODMAP og registrerer 
symptomer. Denne fasen tar sikte på å ”skreddersy” et kosthold tilpasset hver enkels 
individuelle toleranse for type og mengde FODMAP. Dette resulterer i at man kan 
spise et variert kosthold uten mage- og tarmplager, som samtidig ikke er mer 
begrenset enn det behøver å være. Alle som deltar i studien vil i etterkant bli tilbydd 




Tre sentrale spørsmål må besvares når man skal starte med FODMAP-redusert diett 
1. Hvor i kosten finner man karbohydrater? 
2. Hvilke karbohydrater er tungtfordøyelige? 
3. Hvilke matvarer har et høyt innhold av tungtfordøyelige karbohydrater? 
 
1. Hvor i kosten finner man karbohydrater? 
Karbohydrater er en av de tre hovednæringsstoffene som gir energi til kroppen, i 
tillegg til fett og proteiner. Karbohydrater finnes i de fleste matvarer med unntak av i 
rent matfett (smør, margarin, olje) og i rene animalske matvarer som rent kjøtt, 
fjærkre, fisk, skalldyr og egg. Nevnte matvarer kan derfor spises ubegrenset på 
dietten. Vær oppmerksom når disse varene er smaksatt, marinerte eller i form av 
blandingsprodukter (pølser, farse osv.), da de kan inneholde bl.a. løk, hvitløk, melk 
og hvete. Matvarer som inneholder karbohydrater og som derfor potensielt kan 
inneholde FODMAPs, er følgende: 
Mange av de tungtfordøyelige karbohydratene absorberes dårlig av alle mennesker, 
men folk flest tåler likevel FODMAP godt. Grunnen til at personer med irritabel tarm 
som følge av strålebehandling får plager av FODMAP kan være følgende: 
Tarmoverfølsomhet for gassproduksjon 
Ved irritabel tarm er tarmen mer følsom for gassen som blir produsert, 
og den trykkøkningen i tarmen som gassen forårsaker oppleves mer 
smertefull og ubehagelig.  
Bakteriell overvekst i tynntarmen 
Bakterier som normalt sett er lokalisert i tykktarmen, beveger seg over i 
tynntarm. Når FODMAP gjæres av bakterier i tynntarm, vil gassen som 




- korn, kornprodukter, nøtter og frø 
- grønnsaker, frukt, bær og belgfrukter 
- poteter, ris og pasta 
- melk og meieriprodukter 






2. Hvilke type karbohydrater er tungtfordøyelige? 
Det er mange måter å kategorisere ulike typer karbohydrater på, slik som ”raske og 
langsomme” eller ”sukker, stivelse og fiber”. FODMAP-karbohydrater er gruppert 
etter antall sukkerenheter. Nedenfor er en oversikt, men det er ikke nødvendig å 





Monosakkarid 1 Fruktose 
Disakkarid 2 Laktose 
Oligosakkarid 3-10 Fruktaner (FOS: Frukto-oligosakkarider og inulin) 
Galaktaner (GOS: Galakto-oligosakkarider)  
Polysakkarid >10 Ingen 
Polyoler   Sukkeralkoholer og søtstoff som ender på ”-ol" 
Sorbitol, xylitol, mannitol, maltitol, isomalt, lactitol 
 
 
3. Hvilke matvarer har et høyt innhold av tungtfordøyelige karbohydrater? 
Å følge en FODMAP-redusert diett innebærer ikke at man skal ekskludere alle 
matvarer som inneholder karbohydrater, men å begrense de matvarene som har et 
høyt innhold av tungtfordøyelige karbohydrater. En oversikt over slike matvarer og 
hvilke matvarer som har lavt innhold er fremstilt i tabellene i det vedlagte heftet. 
Disse er kategorisert etter matvaregrupper. Det er viktig å beholde karbohydrater i 
kosten mat da matvarer med små mengder FODMAPs både kan og bør inngå i en 
sunt og variert kosthold. Karbohydrater uten FODMAP er: 
- Glukose (druesukker) i frukt og bær 
- Sukrose (vanlig sukker) som bør begrensen av hensyn til generell helse 
- Stivelse (lange glukosekjeder) i poteter, korn, pasta, ris og rotgrønnsaker  
- Kostfiber (lange ufordøyelige kjeder) i grove kornprodukt, frukt og grønnsaker.  
 
NB! Toleranse av kostfiber vil være individuelt. Kostfiber er i likhet med FODMAPs 
også tungtfordøyelige karbohydrater, men forekommer som større forbindelser. Man 
skiller mellom vannløselige og ikke- vannløselige, og de førstnevnte er gunstige.  
 
FODMAP-redusert kost er ikke det samme som lavkarbo eller glutenfri kost!  
Inneholder	ikke	FODMAP	
FODMAP-kilder	




Utfordringen ved å gå på en FODMAP-redusert diett er å lære seg hvilke matvarer 
som inneholder de tungtfordøyelige karbohydratene og å kunne finne disse i 
varedeklarasjoner og innholdslister. I starten kan det virke overveldende og 
komplisert, men etter hvert lærer man seg hva man skal se etter, og man vil bli 
mindre avhengig av å slå opp i listene. 
 
 I det vedlagte heftet er det tabeller over matvarer som har lavt innhold av FODMAPs 
og kan spises fritt, har høyt innhold av FODMAPs og bør unngås, og varer med 
moderat innhold av FODMAPs som kan spises i begrensede mengder. 
Porsjonsmengden i gram som er oppgitt gjelder mengder en ikke bør overskride 
innenfor et måltid. Det er viktig å påpeke at selv om man holder seg innenfor de 
anbefalte mengdene av en matvare, må man samtidig passe på at man ikke inntar 
mange ulike matvarer med moderat innhold i ett og samme måltid. Da kan den totale 
mengden FODMAPs overskride toleransegrensen. Dette gjelder også om man inntar 
veldig store mengder av varene i lav FODMAP- kategorien. Derfor er det lurt å holde 
seg innenfor de anbefalte og ”normale” porsjonsstørrelsene, samt å fordele 
karbohydratinntaket over flere måltider. Det er viktig å huske på at listene er ment 
som oppslagsverk, hvor man kan sjekke innholdet i de varene man bruker selv. 
Listene inneholder mange matvarer som mange aldri bruker, eller har kjennskap til i 
det hele tatt.  
 
Tabellene er basert på matvarelistene til Julianne Lyngstad, som har utarbeidet dem 
ved hjelp av mobilapplikasjonen ”The Monash Uni Low FODMAP Diet”. Om du har 
en smarttelefon er det anbefalt å kjøpe denne applikasjonen. Vi vil refundere 
kostnadene for denne om det er ønskelig, bare spør etter et refusjonsskjema. Det 
finnes også en nyutviklet norsk applikasjon som heter Mollyosa. Denne er detaljert 
og fin, men vi kan ikke garantere at all info der stemmer.  
Det anbefales å bruke facebook gruppen ”Low FODMAP-norsk gruppe” for å motta 
og dele erfaringer, oppskrifter og utfordringer med andre. Det er også gitt ut mange 
norske bøker om dietten, som er å finne hos bokhandleren. Det finnes utallige 
nettsteder med informasjon om dietten, og det er viktig å ikke lese ukritisk overalt, da 
dette kan være mer forvirrende enn oppklarende. Om du skulle ha spørsmål, ta 
heller kontakt med studieholder.  
Andre nyttige linker: 
- Nasjonal kompetansetjeneste for Funksjonelle Mage-tarm sykdommer 
www.helse-bergen.no/nkfm  
- www.lowfodmapnorskgruppe.blogspot.no 






PRAKTISKE RÅD VED FODMAP-REDUSERT KOST 
 
Frokost/Lunsj/Kvelds 
• 2 skiver surdeigsbrød av spelt eller glutenfritt brød/knekkebrød/rundstykker 
med pålegg 
• Havregrøt på laktosefri melk, med bringebær, jordbær, blåbær eller banan 
• Havregryn eller cornflakes med laktosefri melk/biola/yoghurt/kesam 
• Hjemmelaget müsli av havregryn, rosiner og nøtter 
• Omelett (med eks. skinke, hvitost, potet, paprika, brokkoli, squash, oliven) 
• Salat  
o Grønn salat, tomat, agurk, paprika, vårløkblader, oliven, melon 
o Glutenfri pasta 
o Kylling/kjøtt/egg/fisk/sjømat 
o 1 ss Pinjekjerner eller gresskarkjerner 
Middag 
• Rene produkter av kjøtt, egg, fisk og sjømat  
• Blandingsprodukter av kjøtt/fisk – les innholdslisten nøye! 
• Poteter, ris, glutenfri pasta, risnudler, quinoa 
• Eggeretter 
• Pannekaker med havremel, glutenfritt mel og laktosefri melk 
• Pizza med glutenfri bunn og FODMAP-redusert pizzafyll 
• Nachos (tortillachips) med kjøttdeig, hvitost og grønnsaker  
• Hjemmelaget suppe med grønnsaker, kjøtt osv.  
• Stekte grønnsaker/ wok  
• Tilsett: oljer, sitronsaft, laktosefri rømme/kesam, friske urter, chili, ingefær, 
lønnesirup, salt og pepper, hvitløksolje (la hvitløksfedd trekke i olje en uke, 
fjern så hvitløksbitene, eventuelt frese hvitløk i olje for så å plukke ut bitene – 
obs. dette fungerer ikke om det kokes i vann)  
Thousand Island dressing (Idun), selskapsdressing (Salatmesteren).  
Pålegg 
• Rene kjøttpålegg 
• Egg 
• Reker og annen sjømat (stabburet makrell i tomat)  
• Rene fiskepålegg (røkelaks, tunfisk) 
• Kaviar, majones 
• Avokado (noen spiseskjeer) 
• Ost: hvitost, brie, cottage cheese (noen spiseskjeer), cheddar, edamer, 
mozarella, camembert, fetaost 
• Syltetøy: jordbær, bringebær, blåbær 
• Peanøttsmør 
• Banan 




- Lav-FODMAP frukt eller grønnsaker 
- En liten neve nøtter (peanøtter, paranøtter, valnøtter, hasselnøtter, mandler)  
- Laktosefri mager kesam eller laktosefri yoghurt med lav-FODMAP frukt/bær 
- Riskaker med pålegg  
- Müslibar (oppskrift på lyngstadernæring.no)  
- Matmuffins av egg og tilbehør 
-  
Snacks 
• Sorbet-is, vannis (av eks. Fun-light med lav-FODMAP frukt/bær)  
• 1 lite glass moothie av lav-FODMAP frukt/bær, banan, laktosefri yoghurt 
• Fruktsalat med laktosefri meieriprodukt  
• Glutenfrie kjeks og kaker – les innholdslisten nøye! 
• Havrekjeks med nøtter og mørk sjokolade  
• Pannekaker/vafler av spelt/glutenfritt mel og laktosefri melk  
• Riskaker (naturell eller salt) med eks, banan/peanøttsmør  
• Tortillachips, popcorn,potetchips (salt)  
• Nøtter  
• Mørk sjokolade (70% kakao), Non-stop 
• Mentos mint, Ahlgrens biler, Nidar lakrisbåter, vepsebol, Haribo stjernemix, 
vingummi, smågodt uten FODMAPs, 
• Av tyggis og pastiller/drops er de sukkerholdige trygge  
 
Obs! 
- Ikke alle glutenfrie produkter er lav-FODMAP (se etter inulin, fruktose, 
eplefiber, epleekstrakt, betefiber, roefiber, honning, soyamel, løk osv.) 
- Konsentrert fruktjuice (eple/pære) brukes i blant som søtning 
- Dipp og dressing inneholder ofte løk og hvitløk 
- Smaksatt vann kan inneholde fruktose 
- Yoghurt kan være tilsatt fruktose 
- Inulin kan finnes i yoghurt, brød og müsli (som fiber eller prebiotikum) 
- Dersom du reagerer på mye kostfiber, begrens matvarer med mye fiber, og 
velg heller fine produkter enn grove.  En gradvis økning av fiber kan bedre 
toleransen.  
 
På varedeklarasjonen skal alle ingrediensene oppgis i rekkefølge etter vekt. 
Den ingrediensen det er mest av nevnes først, og den det er minst av til sist. 
Bruk denne kunnskapen når du skal vurdere om en matvare kan inngå i 
kostholdet ditt.  Små mengder FODMAP går som regel bra. Står for eksempel 
hvete listet opp sent i ingredienslisten inneholder matvaren så lite at de aller 
fleste tåler det.  
Unntak: Søtstoffene som ender på –ol (Tabell 3), løk og hvitløk bør unngås 
selv i små mengder i eksklusjonsperioden.  
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ET LITE UTVALG OPPSKRIFTER  
 
Grove hjemmelagde knekkebrød (to brett)  
- 3 dl havregryn/havremel (evt. rismel, bokhvetemel, hirseflak, glutenfri 
melblanding)  
- 1 dl gresskarkjerner 
- 1 dl sesamfrø  
- 1 dl solsikkefrø  
- 1 dl linfrø  
- 3 ss havrekli  
- 2 ss fiberhusk  
- 1 ts salt  
- 4-5 dl vann  
Slik gjør du: 
Bland sammen alle ingrediensens og la røren svelle i 10 minutter. Fordel deigen 
med en slikkepott over 2 stekebrett dekket med bakepapir (bruk gjerne flergangsbruk 
bakepapir). Stek på 165°C i ca. 35 minutter. Ta brettene ut og skjær opp ruter med 
et pizzahjul. Bytt plass på brettene og stek i ytterligere 35 minutter. Temperatur og 
steketid varierer fra ovn til ovn, pass på underveis og ha på varmluft eller ha en liten 
glippe i ovnsdøra.  
 
Grovt brød (1 stykk) 







- 2 ts. bakepulver 
- 1 ts. sukker  
- 1 pk tørrgjær 
- 1 ss linfrø 
- 1-2 ss olje (kan sløyfes) 
- 1 egg 
- 5 dl lunkent vann  
Slik gjør du: 
Ha tørrgjær og sukker i det lunkne vannet og bland godt. Tilsett resten av 
ingrediensene og kna deigen. La den heve på et lunt sted i minst 50 minutter, til 
dobbel størrelse. Ha deigen i en brødform (1 liter) og la den etterheve i 15 minutter. 
Stekes på 200°C i 40-50 minutter på nederste rille i ovnen.  
 
Banan-og havregrynspannekaker 
Slik gjør du: 
Mos ½-1 banan, 1-2 egg og ½-1 dl havregryn med en stavmikser. Fordel røren på 3-
4 mellomstore pannekaker/lapper i en stekepanne og stek dem på middels varme i 
ca. 1 min på hver side.  
 
Pannekaker og vafler generelt: ta utgangspunkt i vanlig oppskrift og bytt ut hvetemel 
med ca 2/3 glutenfritt mel og 1/3 havremel. Melken erstattes med laktosefri melk.  
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Lav-FODMAP, glutenfri gjærdeig (til pizza, pitabrød eller rundstykker)  
- 150 ml laktosefri melk 
- 150 g laktosefri kesam  
- 190 g Toro lys glutenfri melblanding + 50 g til utbaking  
- 30 g smeltet smør 
- ½ pk. tørrgjær 
- 1 ts. sukker 
- 2 ts. fiberhusk  
- 1/3 ts. hjortetakksalt (viktig!)  
Slik gjør du: 
Varm opp melk, kesam og smør til ca. 38-40°C. Tilsett sukkeret og tørrgjæren og 
visp til det er løst opp. Bland sammen resten av det tørre, og tilsett væsken. Rør 
godt. Deigen er ganske løs, og det skal den være. La den så heve i ca. 1 time.  
Kna så deigen godt med en god del mel på bordet.  




Scones (8-10 stk.)  
 
- 145 g Toro lys, glutenfri melblanding  
- 40 g havremel  
- 1 ts bakepulver 
- 1 ts salt 
- 1 ts sukker  
- 60 g smør 
- 40 g parmesan-ost (kan sløyfes)  
- 100 g cottage cheese (kan byttes med laktosefri melk/yoghurt)  
- 1 dl laktosefri melk  
- 1 egg 
Slik gjør du: 
Bland alt det tørre og smuldre smøret inn. Bland melk og cottage cheese og bruk en 
stavmikser for å jevne ut cottage cheesen. Tilsett egget i blandingen og bland godt. 
Bland det våte med det tørre raskt. Her skal du ikke elte, kna og røre, deigen skal 
ikke bli seig. Settes på bakepapir med skje. 
Stekes på 200 grader i 10-12 min. 
 (denne oppskriften kan også brukes til hamburgerbrød, pølsebrød osv.  
 
Havrekjeks med nøtter og sjokolade (ca. 40 stk.) 
200 g smør/margarin 
2 dl brunt sukker + 2 dl hvitt sukker 
1 ts vaniljesukker 
2 egg 
3 dl glutenfri melblanding 
½ ts salt 
1 ts bakepulver 
6 1/2 dl havregryn 
ca. 100 g mørk sjokolade, grovhakket 
ca. 80 g mandler, grovhakket 
Slik gjør du: 
Rør smør, sukker og vaniljesukker til det blir 
en porøs smørkrem. Tilsett eggene, ett om 
gangen, og rør godt. Bland i mel, salt og 
bakepulver og rør godt. Tilsett til slutt 
havregryn og hakkete mandler og sjokolade. 
Sett kjeksene med skje på stekeplate dekket 
med bakepapir, og ha litt god avstand 
mellom kakene. Stekes ved 150⁰C i ca. 15 




Siden FODMAP er mange ulike undergrupper av karbohydrater er det slik at det er 
individuelt hvilke typer FODMAP en tåler og ikke tåler. Derfor er det i matvarelistene 
oppgitt forkortelser for hvilke undergrupper av FODMAP matvaren inneholder. Dette 
er relevant informasjon mest i etterkant av fase 2 – reintroduksjon av FODMAPs. 
OF = Oligosakkarider (Fruktaner) 
OG = Oligosakkarider (Galaktaner) 
D = Disakkarid (laktose)  
M = Monosakkarid (Fruktoseoverskudd) 
PM = Polyoler (Mannitol)  
PS = Polyoler (Sorbitol)  
 
GRØNNSAKER OG BELGFRUKTER 







Bok choy/Pak Choy 
Bønnespirer  
Chili, grønn/rød 








Nori (sjøgress)  
Okra  
Oliven  
Paprika (alle farger)  
Pastinakk  
Poteter  





Sikoriblader (endive)  
Sitrongress  





Vårløk (det grønne)  
Yam  
Artisjokk, hermetisert: 56 g (OF, M)  
Avocado: 20-40 g (PS)  
Flaskegresskar: 60 g (OG, PM)  
Fermentert rødkål: 140 g (OF)  
Gresskar, hermetisert: 120 g(OF, OG)  
Selleristilk: 19 g (PM)  
Soltørket tomater: 16 g (M)  
 
BELGFRUKTER  
Chana dal, kokte: 46 g (OG)  
Grønne linser, kokte: 46 g (OF, OG) 
Kikerter, hermetiserte: 44 g (OG) 
Linser, hermetiserte: 46 g (OG) 
Røde linser, kokte: 46 g (OG) 
Urid dal, kokte: 46 g (OG) 
 
*Brokkoli: 47 g (OF, OG, PS)  
*Fennikel: 49 g (OF, PM)  
*Kål: 94 g (PS)  
*Kålrabi: 65 g (PS)  
*Rosenkål: 38 g (OF, PS)  
*Rødkål: 89 g (6 stk.) (PS)  
 
*Listet som lav av Monash University, 
men bør begrenses pga. moderat 
innhold av FODMAPs  
 
Artisjokk (OF, M)  
Asparges (M)  
Blomkål (PM)  
Kassava (OG)  
Hvitløk (OF)  
Jordskokk (OF)  
Løk, gul (OF)  
Løk, rød (OF)  
Mais (OG, PS)  
Portobello sopp (PM) 
Purreløk, hvit del (OF)  
Rødbeter (OF, OG)  
Salatløk (OF)  
Sauerkraut, fermentert (PM)  
Savoykål (OF)  
Shiitake sopp (PM)  
Sjalottløk (OF)  
Sjampinjong + sopp (OF, PM)  
Søtpotet (PM)  
Taro (M)  






Favabønner (M)  
Grønne erter (OG) 
Kidneybønner (OF, OG) 
Kikerter (OG) 
Limabønner (OF, OG) 
Mungbønner (OF, OG) 
Soyabønner (OF, OG) 
Splitterter (OF, OG), flate (OF, 
OG, PM)  
Sukkererter, runde (M) 
Tomatbønner (OF, OG, M)  
* Løk og hvitløk: Disse blir ofte brukt i pulverform og kan skjule seg bak ”krydder” i ingredienslisten 
Appendix 5: FODMAP lists
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FRUKT OG BÆR  
 
NØTTER OG FRØ 






















Hasselnøtter - 10 stk (OF, OG) 
Mandler - 10 stk (OF, OG)  
 
NØTTER  
Cashew (OF, OG) 
Pistasjnøtter (OF, OG)  
 
 































*Begrens inntaket frukt og bær 
til 2-3 à 100 gram selv av lav-
FODMAP typer  
 
FRUKT  
Avocado: 40 g (PS)  
Banan, moden: 3⁄4 banan (M) 
Granateple: 0,5 dl frø (OF) 
Kokosnøtt: 96 g (PS)  
Kokos, tørket: 37 g (PS)  
Longan: 10 stk (PS)  
Rambutan: 4 stk (OF)  
 
TØRKET FRUKT  
Tranebær, tørket: 26 g (OF)  














* Uansett type (lav/moderat/høy) 
vil visse former frukt være høy 
FODMAP: 
- Fruktjuice 
- Større porsjoner av frisk 
frukt/smoothie 
- Hermetisk frukt i egen 
juice 




Aprikos (OF, PS)  
Eple (M, PS)  
Fersken (PS)  
Fiken (M)  
Grapefrukt (OF)  
Granateple (OF)  
Guava, umoden (M)  
Litchi, Lychee (PS)  
Mango (M)  
Nektarin (OF, PS)  
Persimmon (sharon) (OF)  
Plomme (OF, PS)  
Pære (M, PS)  
Tamarillo (M)  
Vannmelon (M, OF, PM)  
 
BÆR  
Bjørnebær (PS)  
Boysenbær (M)  




TØRKET FRUKT  
Dadler (OF)  
Korinter  
Rosiner (OF)  
Svisker (OF, PS)  
Tørket ananas (OF)  
Tørket aprikos (OF, PS)  
Tørket eple (M, PS)  
Tørket fiken (OF)  
Tørket gojibær (OF)  
Tørket mango (OF)  
Tørket papaya (OF)  
Tørket pære (M, PS)  
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MEL, KORN OG PASTA 
LAV FODMAP (SPIS)  MODERAT FODMAP 
(BEGRENS) 
HØY FODMAP (UTELUKK)  










Quinoamel Quinoaflak  
Quinoa  
Ris, brun  
Ris, fullkorn 
Ris, hvit  












Sobanudler (av bokhvete) 
Quinoa-pasta  
 
Glutenfri pasta produseres 
av eks. Schar, Semper og 
Barilla  
 
*Inneholder mindre enn rug 
og hvete, men bør unngås i 
restriksjonsfase. Ved 
surdeigsbakt speltbrød har 
gjæringsprosessen brutt ned 
noe FODMAP 
** Obs. noen inneholder soya 
MEL OG KORN  
Bokhvete, hel: 54 g (OF)  
Havregryn: 47 g (OF, OG)  
Havrekli: 2 ss (OF, OG)  
Havremel: 47 g (OF, OG)  
Riskli: 2 ss (OF)  
 
CEREALER  
Cornflakes: 30 g (OF)  
Puffet ris: 30 g (OF)  
 
MEL OG KORN  
Amarant (OF)  
Bulgur (OF)  
Bygg (OF, OG)  
Couscous av hvete (OF)  
Couscous av ris og mais (OF)  
Durumhvete (OF)  
Emmer (OF)  
Enkorn (OF)  
Ertemel (OG)  
Grahamsmel  
Hvete (OF) ** 
Kamut (OF)  
Kikertmel (OG)  
Kruskakli/hvetekli (OF) 
Linsemel  
Lupin (OF)  
Mandelmel (OF)  
Rug (OF, OG)  
Soyaflak (OG)  
Soyamel (OG)  
Spelt (OF)  
Triticale (Rughvete) (OF, OG) 
 
Fiberrike glutenfrie mel- 
blandinger (OF)*  
 
PASTA  
Glutenfri fiberrik pasta (OF)* 
Hvetenudler (OF, M)  
Gnocci (OF)  
Pasta/spagetti av hvete (OF)  
Speltpasta (OF) 
 
*Les ingredienslisten: Kan 
inneholde soyamel, inulin, 
sikorirot eller roefiber.  
**Kan oppgis med navnene: 
durum, spelt, semule, bulgur, 
coscous og gluten  
* Cornflakes: kan ha malt, maltekstrakt og honning. Den glutenfrie fra Schar er lav-FODMAP 
* Havre: trenger ikke være glutenfri med mindre cøliaki er påvist. Mengdene oppgitt er 
basert på australsk havre og mengder opp mot 100 g av norsk havre skal vise seg 
tolerabelt. Vurder egen inntaksgrense 
* Glutenfritt: gluten er et protein som pasienter med cøliaki reagerer på, og trengs ikke 
unngås i FODMAP-redusert diett. Grunnen til at mange glutenfrie produkter er egnet, er at 
de er laget av alternative kornsorter som også er lavFODMAP. Selv om glutenfrie produkter 
er laget av lavFODMAP kornsorter kan de likevel være tilsatt høyFODMAP ingredienser som 
eplefiber, inulin, epleekstrakt, fruktose, honning, løk, betefiber og roefiber.  
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MELK, MEIERIPRODUKTER OG ALTERNATIV TIL MELK  
LAV FODMAP (SPIS)  MODERAT FODMAP 
(BEGRENS) 
HØY FODMAP (UTELUKK)  
MELK OG MEIERIPRODUKTER 
Laktosefri gresk yoghurt  
Laktosefri kremfløte  
Laktosefri lettrømme  
Laktosefri mager kesam  
Laktosefri matfløte  
Laktosefri melk  
Laktoseredusert melk  
Laktosefri yoghurt naturell  
Laktosefri yoghurt blåbær/vanilje  
Litago, lettere sjokolade  
Margarin  
Meierismør  
Sorbet-is av lav-FODMAP frukt/bær  





Camembert Cheddar  
Chevre  
Cottage cheese (4 ss)  
Edamer Emmentaler  
Fetaost (i blokk)  
Havartiost  
Hvit geitost  




Pultost   
Sveitserost  
Smøreost, kavli  
 





Haloumi: 100 g (D)  
Kremost: 81 g (D)  
Ricotta: 80 g (D)  
 
Rismelk: 2 dl  
 
MELK OG MEIERIPRODUKTER  
Fløteis (D)  
Geitemelk (D)  
Kefir (D) Kesam (D)  
Kremfløte (D)  
Kumelk (og fra andre pattedyr) (D) 
Matfløte (D)  
Rømme (D)  
Soyayoghurt (OG)  
Vikingmelk (D)  
Yoghurt (D)  
 
OST  
Brunost (D)  
Fetaost i marinade (OF)  
Geitost (D)  
Prim (D)  
 
ALTERNATIV TIL MELK  
Havremelk (OG)  
Soyamelk (OG)*  
 


















VARM OG KALD DRIKKE 
LAV FODMAP (SPIS)  MODERAT FODMAP (BEGRENS) HØY FODMAP (UTELUKK)  
KAFFE*  
Espresso  
Kaffe, koffeinfri, svart  
Kaffe, svart  
Kakao (laktosefri)  





Te, grønn  
Te, hvit  
Te, svart  
 
*Koffein i kaffe og te kan 
trigge symptomer  
 
ALKOHOL*  
1 enhet pr. dag er 
lavFODMAP  
Gin  
Musserende vin (brut 
nature)  
Rødvin  








Brus, sukkerfri uten 
fruktjuicekonsentrat  
Brus, sukkerholdig uten 
fruktjuicekonsentrat  




Appelsinjuice, ferskpresset: 100 ml  
Smoothie av lavFODMAP 
ingredienser 
Tranebærjuice: 250 ml  




























* Brus: vær obs. på at kullsyre kan 
gi oppblåsthet.  




Kaffe med laktoseholdig melk 
(D)  
Kaffe med soyamelk (OG)  
 
TE  
Fennikel-te (OF)  
Kamille-te (OF)  
Løvetann-te (OF)  
Oolong-te (OF)  
Roibos (OF) 
Urte-te med sikorirot (OF)  




Cider (M)  
Dessertvin (M)  
Rom (M)  
 
LESKEDRIKK  
Appelsinjuice fra konsentrat 
(M) Brus, sukkerfri med 
fruktjuicekonsentrat (M)  
Brus, sukkerholdig med 
fruktjuicekonsentrat (M) 
Eplebaserte juicer (M, PS) 
Eplejuice (M, PS)  
Kokosvann (OF, PS)  




VEGAN/VEGETAR – SOYAPRODUKTER 
 
 
Ost fra Wilmersburger  
Tempeh  
Tofu  
Tofutti ost  
Quorn  
 
Tips: Er produktet laget av 
soyaproteiner er det 
lavFODMAP.  
Chana dal, kokte: 46 g (OG) 
Grønne linser, kokte: 46 g (OG, OF) 
Kikerter, hermetiserte: 44 g (OG) 
Linser, hermetiserte: 46 g (OG) 
Røde linser, kokte: 46 g (OG)  
Urid dal, kokte: 46 g (OG)  
 
Silketofu (OG)  
Soyamelk (OG)  
Soyayoghurt (OG)  
 
Tips: Er produktet laget av 





SNACKS, DROPS OG SØTSAKER 
LAV FODMAP (SPIS)  MODERAT FODMAP 
(BEGRENS) 
HØY FODMAP (UTELUKK)  
Drops, sukkerholdige  
Laktosefri fløteis  
Melkefri/laktosefri melkesjokolade 
Mørk sjokolade (over 70 % kakao)  
Potetgull, salt  
Popcorn  
Riskaker, salt  
Tacoskjell  
Tortillachips, salt  
Hvit sjokolade: 30 g (D) 
Melkesjokolade: 30 g (D)  
 
Fløtekarameller (D)  
Iskrem (D)  
Potetgull, krydret (OF)  
Saftis, fruktjuicekonsentrat (M)  
Sukkerfrie drops (PS)  
Sukkerfritt godteri (PS)  
Sukkerfrie halslinser (PS)  
Sukkerfrie halslinser med honning 
(PS, M)  
Sukkerfri tyggegummi (PS)  
 
SUKKER OG SØTSTOFF 




Rismalt sirup  
Sukker, brunt  
Sukker, hvitt  
Sukker, palme 




Acesulfat K  
Aspartam  





*1-2 ss sukker per måltid. Kan sammen med 
frukt og bær gi symptomer  
SUKKER  
Agavesirup (M)  
Bjørkesøt  
Fruktose (M)  
High fructose corn sirup (M)  
Honning (M)  
Maissirup  
Molasse (M)  
Sukrin, GOLD  
Yaconsirup (OF)  
 
SØTSTOFF  
Isomalt – E953  
Laktitol – E966  
Maltitol – E965  
Mannitol – E421  
Polydextrose – E1200  
Sorbitol – E420  




LAV FODMAP (SPIS)  MODERAT FODMAP 
(BEGRENS) 
HØY FODMAP (UTELUKK)  


























(carob powder) – 1 ts (OF)  
Eplesyre  - ikke testet men 
sannsynligvis lav  
Chikorirot ekstrakt (OF)  
Eplefiber (OF)  
Epleekstrakt (OF) 
Fruktjuicekonsentrat (M)  
Fruktooligosakkarider/FOS (OF)  
Galaktooligosakkarider/GOS (OG) 
Fruktose (M)  
High fructose corn sirup (M)  
Inulin (OF)  
Isomalto-oligosakkarider (OF) Laktitol 
(D)  
Laktulose (D) 
Sukkerroefiber/betefiber/roefiber (OF)  
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KRYDDER, URTER, SMAKSTILSETNINGER OG FERDIGSAUSER 
LAV FODMAP HØY FODMAP 











































Fond Cups Kylling (Maggi)  
Fond Cups Okse (Maggi)  
Glutenfri brun saus (Toro)  
Glutenfri hvit saus (Toro)  




Kyllingfond (touch of taste)  
Oksefond (touch of taste)  
Kalvefond (touch of taste)  
Fiskefond (touch of taste)  
Majones 
Oljer m/u smak  
Riseddik  









Vær obs på at produsentene kan 
gjøre endringer i produktene sine. 
Les derfor alltid ingredienslisten 
når du velger et ferdigprodukt.  
* En del ketchup inneholder 
løkpulver 
** Chili og rød paprika inneholder 










































LAV FODMAP (SPIS)  MODERAT FODMAP 
(BEGRENS) 
HØY FODMAP (UTELUKK)  





Kaviar (Mills)  
Kyllingfilet naturell (Solvinge) 
Laktosefri kremost naturell  
Laks, gravet 
Laks, røkt  
Makrell i tomat (Stabburet)  
Makrell, skinnfri (King Oscar) 
Magerost (Kavli)  
Majones  
Majones, lett  
Peanøttsmør  
Peppermakrell (Stabburet)  
Reker  
Rekeost (Kavli)  
Rekesalat (Delikat)  
Roastbiff (Gilde)  
Skinke, kokt (Gilde)  
Skinkeost (Kavli)  
Skinke, speket  
Strandamør  
Syltetøy, blåbær  
Syltetøy, bringebær  
Syltetøy, jordbær  
Sjokade  
Våssafår (Stabburet)  
 
Ikke glem lavFODMAP- 
grønnsaker på brødskiva!  
 
Kremost: 4 ss (D)  
 
Brunost (D)  
Krydderost (OF)*  
Leverpostei (OF, D)*  
Nugatti (OF, OG, D)  
Prim (D)  
Salami (OF)*  
Syltetøy av høyFODMAP frukt og 
bær.  
Syltetøy, solbær (OF)  




*Inneholder ofte løk- og 
hvitløkspulver. Les ingredienslisten.  


















Noen glutenfri melblandinger/hurtigløsninger 
	
BAKEMIKSER 
(Må lages med lavFODMAP-alternativer til melk, kefir, kesam osv.) 
 
Det glutenfrie verksted (meny, spar, allergimat.no)  
- Brød, Fiberbrød, Knekkebrød, Loff, Rundstykker uten gjær 
- Boller, Vafler, Pannekaker 
- Brownies, Cookies 
- Pizzabunn, Paibunn 
- Rundstykker uten gjær  
 
MELBLANDINGER  
Fin Mix      (Semper) 
Lys glutenfri melblanding   (Toro)  
Lys glutenfri melblanding, kaker  (Toro)  
Glutenfri pizzabunn    (Villa Paradiso – allergimat.no) 
Grov og halvgrov melblanding   (Cornells alternativ – allergimat.no og helsekostbutikker)  
Havremel (AXA, Møllerens) – Eventuelt kan man lage selv ved å male 
havregryn med stavmikser eller blender  
     Husk mengdebegrensning på ca. 47 g per måltid.  
 
FERDIGE BRØD/KNEKKEBRØD  
Havreknäcke     (Semper) 
Rosmarinknäcke    (Semper)  
Havrerundstykker, glutenfrie   (Hatting)  
Havrebrød, glutenfritt   (Hatting)  
Chiabrød     (Meny)  
Surdeigsbrød av 100 % spelt   - hos bakeren (eks. Godt Brød)  
Speltlomper (Aulie Speltlomper med havre (Kiwi)  - innhold av spelt er 
så lavt at et par lomper regnes som lav/moderat FODMA  
 (begrens til maks 2 per dag)   
Maisbrød Ymse slag, sjekk ingredienslisten for krydder ol.  





PRODUKTER MED HØYT FODMAP-INNHOLD (kan ikke brukes i streng fase)  
MELBLANDINGER  (Høy FODMAP)  
Grov Glutenfri Mix   (Semper) (sukkerroefiber)  
Glutenfri mix    (Semper) (melk)  
Grov glutenfri melblanding   (Toro) (roefiber)  
 
 
FERDIGE BRØD/KNEKKEBRØD (Høy FODMAP)  
Gluten- og laktosefri knekkebrød (OF)  (Wasa, Schar, Toro 1-2-3)  
Superknäcke Chia   (Semper)  
Mørkt glutenfritt brød (ferskt)  (Coop)  
 
*Vær obs på fiberrike glutenfrie brød/melblandinger: De kan ofte inneholde et fiber kalt 
sukkerroefiber/betefiber/roefiber/sukkerbetefiber som kan trigge symptomer hos IBS-pasienter. 
Produktene kan også innholde andre FODMAPs som inulin, løk, hvitløk, epleekstrakt, fruktose og 
honning.  
	
Overholdelse av lav-FODMAP dietten gjennom 4 uker 
 
Hvor fornøyd er du med lav-FODMAP dietten som symptomlindring?  
 
Svært fornøyd                                                                         Svært misfornøyd 
 
0%                                                                                                          100% 
 
 




Ο Kun dersom jeg får videre veiledning 
 
 
Hvis nei, hvorfor: 
Ο For tidkrevende 
Ο Savner for mange matvarer 
Ο Ble ikke bedre 
Ο For dyrt 
 
 
Hvor nøye har du fulgt lav-FODMAP dietten gjennom de 4 ukene? 
 
Ikke fulgt den i det hele tatt        Kun spist lav-FODMAP mat                                                                                                                                                                       
  




Hvor ofte hadde du avvik fra dietten løpet av de 4 ukene: 
Ο Ingen ganger 
Ο 1-5 ganger i løpet av de 4 ukene 
Ο 1-3 ganger i uken 
Ο 4-6 ganger i uken 
 
Hvor store mengder FODMAPs inntok du ved avvik fra dietten? 
Ο En munnfull 
Ο 2-5 munnfull 
Ο Et helt måltid 




Hvor lenge gikk du på dietten før du spiste matvarer med FODMAPs : 
Ο Ingen dager 
Ο 1-3 dager 
Ο 4-7 dager 
Ο 2-3 uker 
Ο 3-4 uker 
 
Appendix 6: Compliance questionnaire for low FODMAP diet during 4 weeks  
 
Hvilken matvarer inneholdt avvik fra dietten: 
Ο Fruktoseholdige matvarer som eple, pære, honning, juice, tørket frukt (rosiner, svisker, aprikos), 
asparges  
Ο Laktoseholdige matvarer som melk/fløte/yoghurt og matvarer med laktose (vafler, boller, kaker, is 
etc.), melkesjokolade. 
Ο Fruktanholdige matvarer som inneholder hvete, rug og bygg som for eksempel brød, boller, vafler, 
kjeks, middagsmat med hvetemel. 
Ο Fruktanholdige matvarer som inneholder løk eller hvitløk, f.eks middagsmat, krydder, ferdigretter.  
Ο Galaktanholdige matvarer som bønner, linser, kikerter eller pistasjnøtter.  
Ο Polyoler som man finner i sukkerfrie pastiller eller tyggis. 




Hvordan synes du det var å følge dietten: 
 
Veldig lett           Veldig utfordrende 
            
  0%                                                                                                      100% 
  
 
Hvorfor spiste du matvarer som inneholdt FODMAPs: 
Ο Spiste kun lav-FODMAP mat 
Ο Ikke tilgang på lav-FODMAP mat på restaurant/gatekjøkken 
Ο For tidkrevende å lage lav-FODMAP mat 
Ο Hadde lyst på mat med FODMAP 
Ο Lav-FODMAP mat var for dyr 
Ο Visste ikke at matvaren inneholdt FODMAPs 
 
 
Hvor fornøyd er du med informasjonen du fikk om dietten: 




Ο Meget misfornøyd 
 
	
Overholdelse av lav-FODMAP dietten én måned etter diettslutt 
 







Hvor godt har du oppretthold lav-FODMAP dietten etter 1 mnd.? 
 
Gått tilbake til  
Mitt normale kosthold                                 Kun spist lav-FODMAP 
 




Hva er grunnen til at du ikke spiser 100 %  lav-FODMAP lenger? 
Ο Ikke aktuelt, følger fortsatt dietten for fullt 
Ο Merket ikke noe effekt av dietten 
Ο Merket ikke god nok effekt til å ofre mitt vanlige kosthold 
Ο Det er kun noen matvarer jeg reagerer på 
Ο Savnet for mange matvarer 
 
 
Dersom du har fulgt dietten, har du reintrodusert noen FODMAPs? 
Ο Ja 
Ο Nei 
Ο Kun noen matvarer 
Ο Prøvd, men ble dårlig av alt 
 
 
Hvordan synes du det var å reintrodusere matvarer til dietten? 
 
Veldig lett                                                                         Meget vanskelig 
 
0%                                                                                                       100% 
 
 
Hva var utfordrende med reintrodusering av matvarer: 
Ο Visste ikke hvordan jeg skulle gjøre det 
Ο At jeg mest sannsynligvis kom til å få symptomer av den matvaren 
Ο Vanskelig å skille «normale symptomer» med strikt diett (jeg ble ikke helt frisk med 
dietten) og symptomer jeg evt får når jeg innfører ulike FODMAPs igjen 
Ο Vanskelig å vite om jeg fikk symptomer fra akkurat den matvaren 
Ο Hadde ikke problemer med re-introdusering 
Ο Ville ikke reintrodusere noen matvarer 
 
Appendix 7: Compliance questionnaire for low FODMAP diet 4-6 weeks after intervention  
 
Hva var det du prøvde å reintrodusere først? 
Ο Fruktoseholdige matvarer som eple, pære, honning, juice, tørket frukt (rosiner, 
svisker, aprikos), asparges  
Ο Laktoseholdige matvarer som melk/fløte/yoghurt og matvarer med laktose (vafler, 
boller, kaker, is etc.), melkesjokolade. 
Ο Fruktanholdige matvarer som inneholder hvete, rug og bygg som for eksempel brød, 
boller, vafler, kjeks, middagsmat med hvetemel. 
Ο Fruktanholdige matvarer som inneholder løk eller hvitløk, f.eks middagsmat, 
krydder, ferdigretter.  
Ο Galaktanholdige matvarer som bønner, linser, kikerter eller pistasjnøtter.  
Ο Polyoler som man finner i sukkerfrie pastiller, tyggis, avokado, aprikos, blomkål, 
plomme, sopp og vannmelon. 
 
 
Kommer du til å fortsette på lav- FODMAP dietten fremover? 






Hvilken type FODMAP tror du at du ikke tåler? Flere kan krysses av. 
Ο Tåler alle 
Ο Tåler ingen 
Ο Fruktoseholdige matvarer som eple, pære, honning, juice, tørket frukt (rosiner, 
svisker, aprikos), asparges  
Ο Laktoseholdige matvarer som melk/fløte/yoghurt og matvarer med laktose (vafler, 
boller, kaker, is etc.), melkesjokolade. 
Ο Fruktanholdige matvarer som inneholder hvete, rug og bygg som for eksempel brød, 
boller, vafler, kjeks, middagsmat med hvetemel. 
Ο Fruktanholdige matvarer som inneholder løk eller hvitløk, f.eks middagsmat, 
krydder, ferdigretter.  
Ο Galaktanholdige matvarer som bønner, linser, kikerter eller pistasjnøtter.  
Ο Polyoler som man finner i sukkerfrie pastiller, tyggis, avokado, aprikos, blomkål, 








Etter å ha har fulgt en FODMAP-redusert kost i 4 uker, og oppnådd symptomlindring, 
er det på tide å introdusere mat du har unngått i restriksjonsperioden. 
 
Først litt mer om undergruppene av FODMAPs: 
• Fruktose (fruktsukker) finnes i frukt, fruktjuice, bær og honning, ofte sammen 
med glukose. Fruktose absorberes godt sammen med like store mengder 
glukose, men 30-40% av befolkningen absorberer ikke overskuddet av 
fruktose. Inntak av mat som har mer fruktose enn glukose kan derfor skape 
problemer hos de med irritabel tarm.  
• Laktose (melkesukker) finnes i melk og meieriprodukter. Det er et disakkarid 
hvor glukose og galaktose er bundet sammen. Under fordøyelse spaltes disse 
fra hverandre vha. enzymet laktase som produseres i tarmslimhinnen. 
Genetisk laktasemangel er vanlig i store deler av verden og blant innvandrere, 
men sjeldent blant etnisk norske. Tarminfeksjon og skader i tarmen kan gi 
midlertidig eller varig laktasemangel.  
• Polyoler (sukkeralkoholer) er sorbitol og andre søtstoff som ender på –ol. 
Disse absorberes ikke fullstendig i tarmen og kan forårsake diare og luftplager 
hos alle. Ved irritabel tarm kan også mindre inntak gi symptomer. Polyoler 
finnes naturlig i visse typer frukt og grønnsaker, og brukes i sukkerfri 
tyggegummi, drops og pastiller.  
• Fruktaner er korte kjeder av fruktose og finnes i blant annet løk, hvete og rug. 
Galaktaner er også oligosakkarider og finnes i blant annet belgfrukter. Disse 
stoffene brytes ikke ned av enzymene i tynntarmen, men blir i stedet mat for 
tykktarmsbakterier som produserer gass.  
 
Eksempler på matvarer innenfor de ulike FODMAP-gruppene 
 
Fruktaner/galaktaner Laktose Fruktose Polyoler  
Frukt: Plomme, nektarin, 
granateple, vannmelon 
Grønnsaker: Artisjokk, bønner, 
brokkoli, erter, hvitløk, løk, kikerter, 



















Hvete, spelt, rug og bygg 
(Som hovedingrediens i 
















FOS, GOS, oligogalaktose, 
oligofruktose, inulin 
Iskrem  Stor porsjon av: 





sorbitol, xylitol  
Appendix 8: FODMAP Reintroduction phase 
	 2	
Reintroduksjonsfasen 
Hvorfor er reintroduksjonen viktig? 
- Toleransen for FODMAP er individuell 
- Reintroduksjonen kan avdekke hvor mye FODMAP du tåler og om noen 
FODMAP-grupper tåles bedre enn andre 
- Noen FODMAP-holdige matvarer fremmer vekst av gode bakterier i tarm og 
det er trolig ikke ideelt å unngå prebiotiske fibre over lang tid 
- Å følge streng lavFODMAP diett over lang tid kan svekke toleransen for 
FODMAP 
- Streng lavFODMAP-diett kan være upraktisk og sosialt vanskelig å følge 
Hva er målet med reintroduksjonen? 
- Å kartlegge symptomtriggere hos deg 
- Å få svar på hvilke og hvor mye FODMAP matvarer du kan spise uten 
symptom 
- Å oppnå et kosthold med minst mulig restriksjoner og samtidig god 
symptomlindring 
 
Forslag til reintroduksjon  
Etter 4 uker på FODMAP-redusert kost gjeninnfører du FODMAP-gruppene én etter én. 
Start for eksempel med fruktose. Merker du ubehag/plager av dette, bør du gå på FODMAP-
redusert kost til du blir bra igjen (utvaskingsperiode), før du prøver ut neste gruppe. Om du 
ikke merker ubehag ved den første gruppen etter tre dager med gradvis økende mengde, 
kan du gå videre til neste gruppe, for eksempel laktose, uten utvaskingsperiode. Prøv deg 
på den måten gjennom alle gruppene.  
 
Følgende matvarer egner seg godt til uttesting fordi de inneholder mye av én FODMAP-type 
og lite eller ingenting av de øvrige .Start forsiktig og øk etter hvert til normale 
porsjonsstørrelser:   













































Fruktaner:  Hvetebrød 
Løk 










Galaktaner:   Bønner 








Slik går du frem: 
- Start gjerne med den gruppen du har savnet mest 
- Test en FODMAP-gruppe om gangen  
- Start med en liten mengde og øk gradvis til en ”normal” porsjon 
- Test den samme matvaren tre dager i løpet av en uke og øk mengden som 
foreslått. Noen velger å teste annenhver dag fordi det kan ta litt tid før man 
opplever symptomer 
- Registrer symptomene hver dag under testukene. Bruk vedlagt skjema 
 
Hvis du ikke får symptomer av i løpet av minst 3 dager, gjør du følgende: 
- Øk mengden av FODMAP innenfor den hovedgruppen du tester for å 
kartlegge toleranse 
- Noter ned mengden du tolererer 
- Husk at det er ingen grunn til å teste større mengder enn du normalt ville spist 
- Fortsett å spis matvaren (i tolerert mengde) og test neste FODMAP-gruppe 
 
Hvis du får symptomer, kan du gjøre en eller flere av følgende: 
- Avbryte testen og gå tilbake til  å spise lavFODMAP til du oppnår 
symptomkontroll (ca. 2 dager) 
- Test den samme matvaren du fikk symptom av, men reduser til halv mengde 
- Anta at du ikke tolerer matvaren du testet og utelat den fra kosten videre 
- Forsøk en annen matvare innenfor samme hovedgruppe, for eksempel 
hvetebrød i stede for løk. 







Dersom du gjennom utprøvingen finner ut at du tolererer laktose dårlig, kan du ha 
nytte av preparater med laktaenzym, som selges reseptfritt på apoteket. De finnes i 
flere varianter. Kerutabs og Lactrase fungerer ved at man tar 1-3 tabletter/kapsler i 
forbindelse med måltid som inneholder laktose. Disse kan være nyttige ved selskap, 
restaurantbesøk, ferie og lignende anledninger.  
	
Vi anbefaler at matvarer som har gitt symptomer testes igjen med jevne mellomrom 
(eks. etter 2-3 mnd.) da toleransegrensen kan endre seg over tid.  
	
Mange finner ut at de kan ta tilbake flere høyFODMAP-matvarer til kostholdet sitt, 























































Appendix 9: Baseline characteristic questionnaire  
Spørreskjema for gradering av stråleskader  
Basert på RTOG – Late Radiation Morbidity Scoring Scheme 
 
1.  
a) Er du for tiden plaget med diaré?  
 
 
b) Hvis ja, hvor alvorlige er diaréplagene?  













a) Er du for tiden plaget med magekramper?  
(smerter ved avføringstrang)  
 
 























































Appendix 10: Questionnaire for grading of radiation injury based on RTOG
4.  
a) Har du for tiden slim i avføringen?  
 








a) Har du for tiden blod i avføringen?  
(rektale blødninger) 
 










a) Har du blitt operert i tarmen som følge av dine 
stråleskader? 
 
b) Hvis ja, hva var årsaken og hva ble gjort?  
 







a) Har du i den siste tiden hatt problemer med ukontrollerbar avføringstrang?  




























































































































































































































Sjelden/aldri# Noen#ganger# Ofte# Det#meste#av#tiden# Alltid#

















Sjelden/aldri# Noen#ganger# Ofte# Det#meste#av#tiden# Alltid#
















Sjelden/aldri# Noen#ganger# Ofte# Det#meste#av#tiden# Alltid#











































































69# Varte#denne#smerten#30#minutter#eller#lenger?# Sjelden/aldri# Noen#ganger# Ofte# Det#meste#av#tiden# Alltid#
70# Bygget#denne#smerten#seg#opp#til#en#vedvarende,#sterk#smerte?# Sjelden/aldri# Noen#ganger# Ofte# Det#meste#av#tiden# Alltid#











1.  Har du hatt tilfredsstillende lindring av dine IBS-smerter/-ubehag de siste 7 dager? 
Sett en ring rundt svaret ditt.              JA       NEI 
 
2. a) Har du magesmerter? Sett en ring rundt svaret ditt.    JA NEI 
 
b) Dersom ja, hvor sterke er magesmertene? (marker på linja)      
     
   0%                                                                                                       100 %           
         
         0            1            2            3            4            5            6            7            8            9            10     
  
Ingen smerte         Veldig mye smerte 
    
 
c) Oppgi antall dager du har kjent magesmerter i løpet av en 10 dagers periode. Dersom du f.eks. 
skriver 4 betyr det at du har smerte 4 av 10 dager. Om du har smerte hver dag, skriver du 10. 
 
Antall dager med smerte: _________ 
 
 
3. a) Har du oppblåst og/eller spent mage? Sett en ring rundt svaret ditt.  JA NEI 
 
b) Dersom ja, hvor mye plaget er du? (marker på linja) 
 
   0%                                                                                                       100 %           
         
         0            1            2            3            4            5            6            7            8            9            10     
  
Ingen plager         Veldig mye plager  
 
 
4.  Hvor fornøyd er du med dine avføringsvaner? (marker på linja) 
 
   0%                                                                                                                    100 %           
         
         0            1            2            3            4            5            6            7            8            9            10     
  
Veldig fornøyd         Veldig misfornøyd   
 
 
5.  Angi med en strek på linja nedenfor hvor mye dine IBS- plager påvirker livet ditt generelt. 
 
   0%                                                                                                       100 %           
         
         0            1            2            3            4            5            6            7            8            9            10     
  







Lider du av følgende: 
a) Kvalme og/eller oppkast? 
   0%                                                                                                       100 %           
Aldri         Hele tiden   
         0            1            2            3            4            5            6            7            8            9            10     
  
 
b) Vanskelig for å spise opp alt ved måltidet?  
   0 %                                                                                                       100 %           
Aldri         Hele tiden   




   0 %                                                                                                       100 %           
Aldri         Hele tiden   
0      1            2            3            4            5            6            7            8            9            10     
 
 
d) Ryggsmerter?  
   0 %                                                                                                       100 %           
Aldri         Hele tiden   
         0            1            2            3            4            5            6            7            8            9            10     
  
 
e) Uopplagt eller trøtt? 
   0 %                                                                                                       100 %           
Aldri         Hele tiden   
         0            1            2            3            4            5            6            7            8            9            10     
 
 
f) Raping og/eller gassavgang?  
   0 %                                                                                                       100 %           
Aldri         Hele tiden   
         0            1            2            3            4            5            6            7            8            9            10     
 
 
g) Halsbrann?  
   0 %                                                                                                       100 %           
Aldri         Hele tiden   
         0            1            2            3            4            5            6            7            8            9            10     
 
 
h) Hyppig eller plutselig trang til vannlating? 
   0 %                                                                                                       100 %           
Aldri         Hele tiden   




i) Smerter i låret?  
   0 %                                                                                                       100 %           
Aldri         Hele tiden   
         0            1            2            3            4            5            6            7            8            9            10     
  
 
j) Smerter i muskler og ledd? 
   0 %                                                                                                       100 %           
Aldri         Hele tiden   
         0            1            2            3            4            5            6            7            8            9            10     
  
 





NAVN: …………………………………………..…… ALDER: …………………………….. 
 
 
 1. IBS-KRITERIER (Sett ring rundt svaret) 
 
Spørsmål Svar 
1.1 Har du vært plaget av smerter eller ubehag i magen i minst 3 dager per måned i løpet av 
       de siste 3 månedene?           Ja Nei 
1.2 Har du hatt disse plagene i 6 måneder eller mer? Ja Nei 
1.3 Er plagene forbundet med endret hyppighet av avføring?    Ja Nei 
1.4 Er plagene forbundet med endret form eller utseende av avføringen?  Ja Nei 
1.5 Reduseres plagene dersom du får tømt deg skikkelig for avføring? Ja Nei 
 
2. TILLEGGSSPØRSMÅL FOR Å KARAKTERISERE PLAGENE (Sett ring rundt svaret) 
 
Spørsmål Svar 
2.1 Hvis du har diaré, hender det at avføringen er fast inn i mellom?  Ja Nei 
2.2 Hvis du har forstoppelse, hender det at avføringen er løs inn i mellom?   Ja Nei 
2.3 Er ufullstendig tømming av avføring et problem for deg? Ja Nei 
2.4 Har du avføring om natta? Ja Nei 
2.5 Hva har du mest av? 
Diaré 
Forstoppelse 
Om lag likt 
 
 
3. KVANTITERING AV IBS SYMPTOMER 
Angis på en skala frå 0 til 10 der 0 = ingen symptomer og 10 = alvorlige symptomer 
(Kane, Am J Gastroenterol 2003) 





















3.6 Anoreksi (ulyst på mat) 
 
 







































































































SF-12v2® Health Survey  1994, 2004, 2012 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
SF-12® is a registered trademark of Medical Outcomes Trust.  
(SF-12v2® Health Survey Acute, Norway (Norwegian)) 
 
 
Din helse og trivsel 
 
 
Dette spørreskjemaet handler om hvordan du ser på din egen helse. Disse 
opplysningene vil hjelpe oss til å få vite hvordan du har det og hvordan du er i 
stand til å utføre dine daglige gjøremål. Takk for at du fyller ut dette 
spørreskjemaet! 
For hvert av de følgende spørsmålene vennligst sett et  i den ene luken som 
best beskriver ditt svar. 
 
1. Stort sett, vil du si at din helse er: 
2. De neste spørsmålene handler om aktiviteter som du kanskje utfører i løpet 
av en vanlig dag. Er din helse slik at den begrenser deg i utførelsen av disse 









meg ikke i 
det hele 
tatt 
   
 a Moderate aktiviteter som å flytte et bord, 
støvsuge, gå en tur eller drive med hagearbeid ......................  1 ............  2 .............  3 
 b Gå opp trappen flere etasjer ...................................................  1 ............  2 .............  3 
Utmerket Meget god God Nokså god Dårlig 
    
   1    2    3    4    5 
Appendix 15: SF-12
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3. I løpet av den siste uken, hvor ofte har du hatt noen av de følgende 
problemer i ditt arbeid eller i andre av dine daglige gjøremål på grunn av 
din fysiske helse? 
4. I løpet av den siste uken, hvor ofte har du hatt noen av de følgende 
problemer i ditt arbeid eller i andre av dine daglige gjøremål på grunn av 
følelsesmessige problemer (som f.eks. å være deprimert eller engstelig)? 
5. I løpet av den siste uken, hvor mye har smerter påvirket ditt vanlige arbeid 
(gjelder både arbeid utenfor hjemmet og husarbeid)? 
Ikke i det 
hele tatt 
Litt En del Mye Svært mye 
    









Ikke i det 
hele tatt 
     
 a Du har utrettet mindre enn  
du hadde ønsket ............................  1 .............  2 .............  3 ..............  4 ............  5 
 b Du har vært hindret i å utføre 
visse typer arbeid eller 









Ikke i det 
hele tatt 
     
 a Du har utrettet mindre enn  
du hadde ønsket ............................  1 .............  2 .............  3 ..............  4 ............  5 
 b Du har utført arbeidet eller  
andre gjøremål mindre  
grundig enn vanlig ........................  1 .............  2 .............  3 ..............  4 ............  5 
SF-12v2® Health Survey  1994, 2004, 2012 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved. 
SF-12® is a registered trademark of Medical Outcomes Trust.  
(SF-12v2® Health Survey Acute, Norway (Norwegian)) 
6. Disse spørsmålene handler om hvordan du har følt deg og hvordan du har 
hatt det den siste uken. For hvert spørsmål, vennligst velg det 
svaralternativet som best beskriver hvordan du har hatt det. Hvor ofte i 
løpet av den siste uken har du… 
7. I løpet av den siste uken, hvor ofte har din fysiske helse eller følelsesmessige 

















Ikke i det 
hele tatt 
     
 a   Følt deg rolig og harmonisk? .........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 b   Hatt mye overskudd? .....................  1 ..............  2 ..............  3 ..............  4 ..............  5 









Ikke i det  
hele tatt 
    
   1    2    3    4    5 
The effect of low FODMAP-diet in patients with radiation-induced small 
bowel disease  
Pilot study: is a low FODMAP-diet an effective approach for reducing symptoms in 
patients with radiation-induced small bowel disease?  
 
Researcher: Trine Larsen  
Group leader: Trygve Hausken  
Collaborators: Synne Otteraaen Ystad, Gülen Arslan Lied, Nils Hovdenak, Guro 
Vaagbø and Bernd Müller  
 
Background 
Radiation-induced small bowel disease is a common side effect following ionizing 
radiation therapy used to treat cancer in, or in organs surrounding the gastrointestinal 
(GI) tract (1). Because of localization close to specific organs the cancer types related 
to this symptom disease are GI, urological and gynecological cancers. The damage to 
the small bowel gives symptoms that are similar to those seen in irritable bowel 
disease (IBS), and includes abdominal pain/discomfort, bloating, diarrhea, 
constipation, nausea and faecal urgency. In addition anorexia, malabsorptions and 
rectal bleeding can also be seen as a result of radiation damage. The severity and type 
of symptoms vary with the applied dose of radiations used, which areas in GI that are 
affected, the degree of tissue damage and factors other than radiation which might 
decrease blood flow in bowel tissue (hypertension, diabetes, smoking etc.). The most 
frequent cause of these symptoms is small bowel bacterial overgrowth. Other 
contributors to the development of chronic symptoms are the degree of 
immunosuppression during radiation treatment, specific drugs and the degree of 
damage to mucosa, submucosa and GI stem cells (2).  The terms used to describe 
these symptoms vary. Traditionally the term “radiation enteritis” was used, but this 
indicates that there is an inflammation in the bowel, which is not always the case. 
“Radiation enteropathy” or “Radiation-induced small bowel disease/damage 
(RISBD)” are probably more appropriate (1). RISBD is categorized in acute or 
chronic damage. The acute symptoms are more self-limiting and only present during 
the radiation therapy period. In this study we will focus on patients who suffer from 
chronic radiation injury, which develops between 18 months and 6 years after 
radiation therapy is completed. Cancer treatment is steadily improving and the 
number of cancer survivors is increasing (3). Consequently the numbers of patients 
suffering from RISBD also increase, and some reports suggest that 90% of patients 
receiving this type of cancer therapy develop bowel symptoms in some degree (4). 
The condition is known to be underreported, but should be taken seriously as it often 
affects the quality of life (3). One of the reasons that the disease is under diagnosed, is 
both that a clear definition of the symptoms, and a routine management are missing 
(3).  
 
Appendix 16: Study protocol
The available management of chronic RISBD includes antibiotics against bacterial 
overgrowth in small bowel, bile salt sequestering agents, exclusion diets, supportive 
enteral diets, supplements of micronutrients, parenteral nutrition, hyperbaric oxygen 
therapy (HBO), antioxidants, anti-inflammatory agents, endoscopic therapies and 
surgery (1).   
 
In Norway, there are available brochures that are given to the patients after finishing 
radiation therapy where RISBD is noted as a possible side effect. The brochures 
include counseling information about food groups that can be excluded to reduce GI 
symptoms. The principles the patients are encouraged to follow are to eat a diet low in 
lactose and fat and to avoid food that induces bowel gas, contains a lot of spices or 
has a hard baking crust. The brochures also advise patients to eat small and more 
frequent meals, and to distribute the fat intake over several meals (5). To what extent 
this approach is followed is not known. There has also been used a diet low in 
fermentable oligosaccharides, disaccharides, monosaccharides and polyols 
(FODMAP) for this group of patients. The reported results seem to be positive 
regarding improvements in symptoms, but trials on FODMAP exclusion diet have not 
been published (1). 
 
Hyperbaric oxygen therapy (HBOT)  
As changes in the microvascular function are thought to be the principal factor of the 
malfunction of radiation-injured organs, interventions counteracting the resulting 
hypoxia might be beneficial. 
Hyperbaric oxygen treatment (HBOT) is a treatment modality where patients breathe 
100 % oxygen in an ambient pressure exceeding 2 ATA. Hyperoxygenation of 
hypoxic tissues has been shown to stimulate neoangiogenesis in irradiated tissue and 
thereby improve cellular function. In Norway, radiation injury to the GI system is an 
approved indication for HBOT and all elective HBOT is centralized to the Norwegian 
National Unit for Planned Hyperbaric Oxygen Treatment at Haukeland University 
hospital in Bergen. The patients are treated as outpatients in a monoplace chamber 
where they breathe 100% oxygen for 90 minutes daily at an ambient pressure of 2,4 
ATA. They are treated five days a week until a total of 30 treatments (6, 7).  
 
FODMAP is an acronym referring to fermentable oligosaccharides, disaccharides, 
monosaccharides and polyols. These are complex names for a collection of 
carbohydrates commonly found in the modern western diet, highlighted as putative 
triggers of gastrointestinal symptoms (8). FODMAPs are small osmotic active 
molecules that are poorly absorbed in the small intestine and rapidly fermented by 
intestinal bacteria with production of gases (hydrogen, methane, carbon dioxide) and 
short chain fatty acids (SCFAs, e.g., acetic, propionic and butyric acid) (9). The 
resultant increased luminal volume (both water and gas), leads to bloating, flatulence 
and abdominal pain/discomfort. In addition, the increased intestinal gas and water 
delivery together with the generation of SCFAs can alter bowel motility, which may 
contribute to diarrhoea and/or constipation (10). 
Poor absorption of most FODMAPs is common, but this physiological malabsorption 
is usually tolerated in healthy people. Although everyone will experience 
uncomfortable symptoms when ingesting large enough quantities of FODMAPs, the 
threshold and the severity of symptoms will be individual. It has been shown that 
FODMAPs are especially problematic for people with IBS (10).  
 
Dr. Sue Shepherd developed the “low FODMAP diet” in 1999, and since then 
positive results from several high-quality studies have made the diet become 
increasingly accepted and recommended as one of the most effective therapies in 
patients with IBS (11). 
 
Since the symptoms and pathophysiology of IBS and RISBD show similarities, it is of 
significant interest to study the effect of a low FODMAP diet in patients with RISBD 





Questions to be answered: 
1. Are GI symptoms alleviated in patients with RISBD when adapting to a low 
FODMAP diet?  
If so, which symptoms are alleviated and to what degree?  
2. Will a low FODMAP diet have any influence on quality of life in subjects with 
RISBD?  
 
Null hypothesis: There will be no differences in symptoms before and after an 
intervention with low FODMAP diet  
 
Alternative hypothesis: The study objects will experience a relief in symptoms when 
eating a diet low in FODMAP’s  
 
Design and methods  
The study will be conducted as an open, prospective, pilot intervention study with an 
intervention group consisting of approximately 18 subjects. The participants will be 
recruited between August and January 2017 from Norwegian National Unit for 
Planned Hyperbaric Oxygen Treatment, Section for Gynecological cancer at the 
“Women´s Clinic” and Medical Department at Haukeland University Hospital. In 
addition we will make an attempt to recruit patients through advertisement within The 
Association of Gynecological Cancer Patients in Norway, a patient association 
affiliated the Norwegian Cancer Society.  
 
The participants will be contacted by a letter and receive an offer to participate in the 
study. At baseline the subjects will be asked to do sign a written consent, do a 3-day 
prospective food record and answer questionnaires regarding grade of tissue damage, 
symptoms and quality of life. These will be sent to the study holder by mail or e-mail 
in prior to the introduction of the intervention. The subjects will receive diet 
counseling on how to follow a low FODMAP diet by telephone communication, and 
detailed written information about the diet will be sent by mail/e-mail. The 
participants that live in the area close to Bergen, will be asked to meet up in person to 
fill out the forms, and get diet counseling. The intervention period will be four weeks.  
 
At the end of the intervention the participants will again answer the questionnaires for 
symptoms and quality of life, make a 3-day food record and fill out a low FODMAP 
compliance form. During the following six weeks after ending the study, the 
participant will be asked to again fill out the compliance form to see if they to any 
degree are adapting the diet to their regular eating habits.  
 
After the end of the study, participants will be offered to receive counseling on how to 
reintroduce FODMAP’s. This is an approach to find out which of the FODMAP’s are 
giving IBS symptoms in the individual subject.  
 
Study subjects 
Inclusion criteria  
- Subjects between 18-70 years of age 
- Filled informed written consent 
- Patients who suffer from radiation induced small bowel disease 
- Patients referred and accepted for HBOT with IBS-symptoms  
- IBS-symptoms confirmed by the Rome III-criterion  
- IBS-symptoms with/without bleeding  
 
Exclusion criteria 
- Patients already eating a diet low in FODMAP’s (If so they have to stop the 
diet for 3 weeks before entering the study) 
- Patients already receiving HBOT  
 
Data collection  
1. IBS-SSS: IBS-Severity Scoring System  
2. Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders  
3. RTOG: Radiation therapy oncology group – toxicity grading scale  
4. SF-NDI: Short Form Nepean Dyspepsia Index 
5. 3-day prospective food record – analysis with “Kostholdsplanleggeren”  
6. Low FODMAP compliance form  




There is no risk of harm in this study. The intervention and the data collection may be 
perceived as demanding for some, but it will not cause any harm to the participants. 
The study is voluntarily and the participants can withdraw from the study at any point 
without providing any justification. 
The study will not delay the start of HBOT, or affect any other treatment the 
participants are receiving.  
The study will be presented to the Regional Committee for Medical Research Ethics 
(REK). 
 
Data analyzing and statistics 
The data will be summarized in figures and/or tables. SPSS will be used to perform 
statistical analysis.  
 
Timetable 
February – April 2016  Writing of protocol and applying to REK 
June – January 2017   Recruiting of patients and performance of study  
February – March 2017  Data analysis  




Publication plan  
There will be made an effort to get the paper published in an international journal read 
by professions like clinical dietitians, oncologist and gastroenterologists etc.  
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